Bio-Rad Laboratories (BIO) 10-Q 30 Oct 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Oct. 22, 2020
Document Transition Report	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
City Area Code	(510)
Document Quarterly Report	true
Entity Incorporation, State or Country Code	DE
Entity File Number	1-7928
Entity Registrant Name	BIO-RAD LABORATORIES, INC.
Entity Central Index Key	0000012208
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Small Business	false
Entity Tax Identification Number	94-1381833
Entity Address, Address Line One	1000 Alfred Nobel Drive,
Entity Address, City or Town	Hercules,
Entity Address, Country	CA
Entity Address, Postal Zip Code	94547
Local Phone Number	724-7000
Entity Emerging Growth Company	false
Common Class A [Member]
Title of 12(b) Security	Class A Common Stock, Par Value $0.0001 per share
Trading Symbol	BIO
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding		24,740,501
Common Class B [Member]
Title of 12(b) Security	Class B Common Stock, Par Value $0.0001 per share
Trading Symbol	BIOb
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding		5,090,003

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
ASSETS:
Cash and cash equivalents	$ 840,325,000	$ 660,672,000
Short-term investments	314,102,000	453,973,000
Restricted investments	5,560,000	5,560,000
Accounts receivable, net	402,241,000	392,672,000
Inventories:
Raw materials	149,117,000	109,570,000
Work in process	158,577,000	146,131,000
Finished goods	332,534,000	298,306,000
Total inventories	640,228,000	554,007,000
Prepaid expenses	111,296,000	102,331,000
Other current assets	10,109,000	10,940,000
Total current assets	2,323,861,000	2,180,155,000
Property, plant, and equipment	1,404,622,000	1,382,172,000
Less: accumulated depreciation and amortization	923,673,000	882,833,000
Property, plant and equipment, net	480,949,000	499,339,000
Operating lease right-of-use assets	196,652,000	201,868,000
Goodwill, net	291,916,000	264,131,000
Purchased intangibles, net	205,305,000	145,525,000
Other investments	8,439,897,000	4,638,205,000
Other assets	82,351,000	79,636,000
Total assets	12,020,931,000	8,008,859,000
LIABILITIES AND STOCKHOLDERS' EQUITY:
Accounts payable	132,994,000	107,014,000
Accrued payroll and employee benefits	190,091,000	180,084,000
Current maturities of long-term debt and notes payable	426,636,000	426,172,000
Income and other taxes payable	41,646,000	36,285,000
Current operating lease liabilities	34,387,000	35,365,000
Other current liabilities	160,903,000	120,575,000
Total current liabilities	986,657,000	905,495,000
Long-term debt, net of current maturities	12,241,000	13,579,000
Deferred income taxes	1,842,659,000	997,787,000
Operating lease liabilities	172,144,000	176,018,000
Other long-term liabilities	182,085,000	160,923,000
Total liabilities	3,195,786,000	2,253,802,000
Stockholders' equity:
Additional paid-in capital	412,313,000	410,020,000
Retained earnings	8,428,925,000	5,470,779,000
Accumulated other comprehensive loss	83,971,000	(87,348,000)
Total stockholders' equity	8,825,145,000	5,755,057,000
Total liabilities and stockholders' equity	12,020,931,000	8,008,859,000
Accounts receivable allowance for doubtful accounts	19,370,000	20,205,000
Common Class A [Member]
Stockholders' equity:
Common stock	$ 2,000	$ 2,000
Common Stock, Shares, Issued	25,044,738	24,966,035
Common Stock, Shares, Outstanding	24,739,501	24,835,804
Common Class B [Member]
Stockholders' equity:
Common stock	$ 1,000	$ 1,000
Common Stock, Shares, Issued	5,091,003	5,089,532
Common Stock, Shares, Outstanding	5,091,003	5,089,532
Treasury Class A [Member]
Stockholders' equity:
Treasury stock	$ (100,067,000)	$ (38,397,000)
Treasury Stock, Shares	305,237	130,231

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets Parenthetical - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Accounts receivable allowance for doubtful accounts	$ 19,370	$ 20,205
Common Class A [Member]
Common Stock, Shares, Issued	25,044,738	24,966,035
Common Stock, Shares, Outstanding	24,739,501	24,835,804
Common Class B [Member]
Common Stock, Shares, Issued	5,091,003	5,089,532
Common Stock, Shares, Outstanding	5,091,003	5,089,532
Treasury Class A [Member]
Treasury Stock, Shares	305,237	130,231

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Net sales	$ 647,263	$ 560,633	$ 1,755,787	$ 1,687,231
Cost of goods sold	279,952	253,607	778,120	760,674
Gross profit	367,311	307,026	977,667	926,557
Selling, general and administrative expense	198,165	201,622	581,119	610,460
Research and Development Expense	59,546	47,944	160,833	145,641
Segment profit (loss)	109,600	57,460	235,715	170,456
Interest expense	5,728	5,525	17,158	17,352
Foreign exchange (gains) losses, net	776	898	2,478	3,411
Marketable Securities, Unrealized (Gain) Loss	(1,580,350)	390,620	(3,591,509)	(1,384,999)
Other Nonoperating Income (Expense)	1,015	4,367	21,517	26,959
Income before income taxes	1,684,461	(335,216)	3,829,105	1,561,651
(Provision) benefit for income taxes	(369,637)	76,400	(861,940)	(356,462)
Net income attributable to Bio-Rad	$ 1,314,824	$ (258,816)	$ 2,967,165	$ 1,205,189
Basic earnings per share:
Net income per share basic attributable to Bio-Rad	$ 44.24	$ (8.68)	$ 99.75	$ 40.42
Weighted average common shares - basic	29,721	29,831	29,746	29,815
Diluted earnings per share:
Net income per share diluted attributable to Bio-Rad	$ 43.64	$ (8.68)	$ 98.46	$ 39.97
Weighted average common shares - diluted	30,128	29,831	30,137	30,149

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Net Income (Loss) Attributable to Parent	$ 1,314,824	$ (258,816)	$ 2,967,165	$ 1,205,189
Foreign currency translation adjustments	144,902	(103,332)	167,366	(109,888)
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent	333	359	924	501
Net unrealized holding gains (losses) on available-for-sale investments net of tax expense	(122)	433	3,029	4,232
Total other comprehensive income (loss) net of tax	145,113	(102,540)	171,319	(105,155)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	$ 1,459,937	$ (361,356)	$ 3,138,484	$ 1,100,034

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities:
Cash received from customers	$ 1,741,431	$ 1,716,486
Cash paid to suppliers and employees	(1,406,427)	(1,392,653)
Interest paid, net	(11,066)	(11,381)
Income tax payments, net	(51,539)	(42,634)
Investment proceeds and miscellaneous receipts, net	16,336	28,092
Proceeds from forward foreign exchange contracts, net	1,859	185
Net cash provided by operating activities	290,594	298,095
Cash flows from investing activities:
Capital expenditures	(59,685)	(76,934)
Proceeds from dispositions of property, plant and equipment	51	85
Payments for purchases of marketable securities and investments	(184,665)	(266,839)
Proceeds from maturities of marketable securities and investments	242,676	181,108
Proceeds from Sale of Debt Securities, Available-for-sale	75,997	83,315
Payments for Acquisitions, net of cash received	(96,655)	(75,811)
(Payments for) recovery of purchases of intangible assets	(100)	7,383
Proceeds from Divestiture of Businesses	12,240	0
Net cash used in investing activities	(10,141)	(147,693)
Cash flows from financing activities:
Payments on long-term borrowings	(1,780)	(487)
Payments for credit agreement renewal fees	0	(486)
Payments of contingent consideration	(1,724)	(2,477)
Proceeds from Issuance of Common Stock	15,181	9,740
Tax payments from net share settlement	(12,830)	(8,096)
Proceeds from Reissuance of Treasury Stock	0	3,831
Payments for purchases of treasury stock	(100,004)	(20,000)
Net cash used in financing activities	(101,157)	(17,975)
Effect of Exchange Rate on Cash and Cash Equivalents	3,154	(3,239)
Beginning Cash, Cash Equivalents, and Restricted Cash	662,651	434,164
Cash and cash equivalents	840,325	561,071
Ending Cash, Cash Equivalents, and Restricted Cash	845,101	563,352
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	182,450	129,188
Other Current Assets
Cash flows from financing activities:
Restricted Cash, Current	3,763	100
Other Assets
Cash flows from financing activities:
Restricted Cash, Noncurrent	$ 1,013	$ 2,181

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity Statement - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]
Total Stockholders' Equity at Dec. 31, 2018	$ 4,020,331	$ 3	$ 394,342	$ (49,129)	$ 3,722,073	$ (46,958)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	865,195				865,195
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(34,007)					(34,007)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	8,505		8,505
Treasury Stock Reissued at Lower than Repurchase Price	3,831			5,398	(1,567)
Total Stockholders' Equity at Mar. 31, 2019	4,863,855	3	402,847	(43,731)	4,585,701	(80,965)
Total Stockholders' Equity at Dec. 31, 2018	4,020,331	3	394,342	(49,129)	3,722,073	(46,958)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	1,205,189
Proceeds from Issuance of Common Stock	9,740
Total Stockholders' Equity at Sep. 30, 2019	5,131,192	3	396,432	(30,443)	4,917,313	(152,113)
Total Stockholders' Equity at Mar. 31, 2019	4,863,855	3	402,847	(43,731)	4,585,701	(80,965)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	598,810				598,810
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	31,392					31,392
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	7,818		7,818
Proceeds from Issuance of Common Stock	(64)		(64)
Treasury Stock, Value, Acquired, Cost Method	(15,001)			(15,001)
Total Stockholders' Equity at Jun. 30, 2019	5,486,810	3	410,601	(58,732)	5,184,511	(49,573)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	(258,816)				(258,816)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(102,540)					(102,540)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	9,029		9,029
Proceeds from Issuance of Common Stock	1,708		1,708
Treasury Stock Reissued at Lower than Repurchase Price	0		(24,906)	33,288	(8,382)
Treasury Stock, Value, Acquired, Cost Method	(4,999)			(4,999)
Total Stockholders' Equity at Sep. 30, 2019	5,131,192	3	396,432	(30,443)	4,917,313	(152,113)
Total Stockholders' Equity at Dec. 31, 2019	5,755,057	3	410,020	(38,397)	5,470,779	(87,348)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	685,912				685,912
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(61,607)					(61,607)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	9,654		9,654
Proceeds from Issuance of Common Stock	4,068		4,068
Treasury Stock, Value, Acquired, Cost Method	(100,005)			(100,005)
Total Stockholders' Equity at Mar. 31, 2020	6,293,079	3	423,742	(138,402)	6,156,691	(148,955)
Total Stockholders' Equity at Dec. 31, 2019	5,755,057	3	410,020	(38,397)	5,470,779	(87,348)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	2,967,165
Proceeds from Issuance of Common Stock	15,181
Total Stockholders' Equity at Sep. 30, 2020	8,825,145	3	412,313	(100,067)	8,428,925	83,971
Total Stockholders' Equity at Mar. 31, 2020	6,293,079	3	423,742	(138,402)	6,156,691	(148,955)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	966,429				966,429
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	87,813					87,813
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	8,878		8,878
Proceeds from Issuance of Common Stock	(2,797)		(2,797)
Treasury Stock Reissued at Lower than Repurchase Price	0		(338)	365	(27)
Total Stockholders' Equity at Jun. 30, 2020	7,353,402	3	429,485	(138,037)	7,123,093	(61,142)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	1,314,824				1,314,824
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	145,113					145,113
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	10,732		10,732
Proceeds from Issuance of Common Stock	1,080		1,080
Treasury Stock Reissued at Lower than Repurchase Price	(6)		(28,984)	37,970	(8,992)
Total Stockholders' Equity at Sep. 30, 2020	$ 8,825,145	$ 3	$ 412,313	$ (100,067)	$ 8,428,925	$ 83,971

5. Supplemental Cash Flow Infor

5. Supplemental Cash Flow Information Cash Flow, Supplemental Disclosure	9 Months Ended
	Sep. 30, 2020
Supplemental Cash Flow Elements [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	SUPPLEMENTAL CASH FLOW INFORMATION The reconciliation of net income to net cash provided by operating activities is as follows (in millions): Nine Months Ended September 30, 2020 September 30, 2019 Net income $ 2,967.2 $ 1,205.2 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 101.9 99.8 Reduction in the carrying amount of right-of-use assets 27.7 31.1 Share-based compensation 29.3 25.4 Gains on dispositions of securities (0.6) (0.2) Other-than-temporary impairment losses on investment 4.6 1.6 Changes in fair market value of equity securities (3,591.5) (1,385.0) Losses on dispositions of fixed assets 0.3 0.3 Gain on divestiture of a division (11.7) — Changes in fair value of contingent consideration (1.0) (0.6) Payments for operating lease liabilities (27.1) (27.6) (Increase) decrease in accounts receivable (9.6) 30.4 Increase in inventories (83.5) (14.5) (Increase) decrease in other current assets (6.4) 47.9 Increase (decrease) in accounts payable and other current liabilities 79.2 (24.6) Increase (decrease) in income taxes payable 3.1 (2.8) Increase in deferred income taxes 790.1 310.9 Increase in other long term liabilities 19.7 5.5 Other (1.1) (4.7) Net cash provided by operating activities $ 290.6 $ 298.1 1 Non-cash investing activities: Purchased property, plant and equipment $ 6.1 $ 4.5 Purchased marketable securities and investments $ 2.0 $ 2.8
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	The reconciliation of net income to net cash provided by operating activities is as follows (in millions): Nine Months Ended September 30, 2020 September 30, 2019 Net income $ 2,967.2 $ 1,205.2 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 101.9 99.8 Reduction in the carrying amount of right-of-use assets 27.7 31.1 Share-based compensation 29.3 25.4 Gains on dispositions of securities (0.6) (0.2) Other-than-temporary impairment losses on investment 4.6 1.6 Changes in fair market value of equity securities (3,591.5) (1,385.0) Losses on dispositions of fixed assets 0.3 0.3 Gain on divestiture of a division (11.7) — Changes in fair value of contingent consideration (1.0) (0.6) Payments for operating lease liabilities (27.1) (27.6) (Increase) decrease in accounts receivable (9.6) 30.4 Increase in inventories (83.5) (14.5) (Increase) decrease in other current assets (6.4) 47.9 Increase (decrease) in accounts payable and other current liabilities 79.2 (24.6) Increase (decrease) in income taxes payable 3.1 (2.8) Increase in deferred income taxes 790.1 310.9 Increase in other long term liabilities 19.7 5.5 Other (1.1) (4.7) Net cash provided by operating activities $ 290.6 $ 298.1 1 Non-cash investing activities: Purchased property, plant and equipment $ 6.1 $ 4.5 Purchased marketable securities and investments $ 2.0 $ 2.8

5. Supplemental Cash Flow Inf_2

5. Supplemental Cash Flow Information - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Supplemental Cash Flow Elements [Abstract]
Net Income Attributable to Parent	$ 2,967,165	$ 1,205,189
Share-based Compensation	29,300	25,400
(Gain) Loss on Sale of Securities, Net	(600)	(200)
Other than Temporary Impairment Losses on Investments	4,600	1,600
Changes in fair market value of equity securities	(3,591,500)	(1,385,000)
Loss on Disposition of Property Plant Equipment	300	300
Changes in fair value of contingent consideration	(1,000)	(600)
(Increase) decrease in accounts receivable	(9,600)	30,400
Increase in inventories	(83,500)	(14,500)
(Increase) decrease in other current assets	(6,400)	47,900
Increase (decrease) in accounts payable and other current liabilities	79,200	(24,600)
Increase (decrease) in income taxes payable	3,100	(2,800)
Increase in deferred income taxes	790,100	310,900
Increase in other long term liabilities	19,700	5,500
Gain on Disposition of a division	(11,700)	0
Operating Lease, Right-of-Use Asset, Amortization Expense	27,700	31,100
Other Depreciation and Amortization	101,900	99,800
Other	(1,100)	(4,700)
Payments of operating lease liabilities	(27,100)	(27,600)
Net cash provided by operating activities	290,594	298,095
Noncash or Part Noncash Acquisition, Investments Acquired	2,000	2,800
Noncash or Part Noncash Acquisition, Fixed Assets Acquired	$ 6,100	$ 4,500

1. Basis of Presentation and Us

1. Basis of Presentation and Use of Estimates	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure	BASIS OF PRESENTATION AND USE OF ESTIMATES Basis of Presentation In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries. The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented. All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year. The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2019. We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued. The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading. To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions. Use of Estimates The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. Revenue Recognition We recognize revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment, and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recognized until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to customer specifications, which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control in relation to the equipment has occurred at that point as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon customer acceptance because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service. At the time revenue is recognized, a provision is recorded for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, the transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used to determine the stand-alone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance. We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant. Reagent Rental Agreements Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we next must ascertain its lease classification for purposes of applying appropriate accounting treatment as an operating, sales-type or direct financing lease. For purposes of determining the lease term used in performing the lease classification test, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if the customer is reasonably certain to exercise that option, the periods covered by an option to terminate the lease if the customer is reasonably certain not to exercise that option, and the periods covered by the option to extend (or not to terminate) the lease in which exercise of the option is controlled by the Company. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel, the period in which the contract is enforceable is a very short period and therefore the lease term has been limited to the noncancellable period. Generally these arrangements do not contain an option for the lessee to purchase the underlying asset. We concluded that the use of the instrument (referred to as “lease elements”) is not within the guidance of ASC 606 but rather ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After allocation, the amount of variable payments allocated to lease components will be recognized as income under ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Upon our adoption of ASC 842 in 2019, the maintenance services, along with the reagents, are now allocated to the non-lease elements and will be recognized as income in accordance with ASC 606. This change is in accordance with the requirements of ASC 842, and has resulted in a decrease in the amount of rental income and a corresponding increase in the amount of maintenance service revenue that is included in Net sales in our condensed consolidated statements of income. Generally, the terms of the arrangements result in the transfer of control for reagents upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer. Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as very few of such arrangements contain any fixed/minimum lease payments. Further, our reagent rental arrangements are predominantly classified as operating leases, and any sales-type leases represent in aggregate an immaterial amount of lease income. Our reported lease income is primarily variable in nature and is recognized upon delivery or as the reagents are consumed by the customer. Revenue allocated to the lease elements of these reagent rental arrangements represents approximately 3% of total revenue for both the three and nine months ended September 30, 2020, and September 30, 2019, and is included as part of Net sales in our condensed consolidated statements of income. Contract costs: As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income. Disaggregation of Revenue: The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Europe $ 220.9 $ 181.9 $ 590.6 $ 556.1 Asia 142.0 120.7 382.3 354.3 United States 250.4 225.8 685.4 674.0 Other (primarily Canada and Latin America) 34.0 32.2 97.5 102.8 Total net sales $ 647.3 $ 560.6 $ 1,755.8 $ 1,687.2 The disaggregation of our revenue by industry segment sources is presented in our Segment Information footnote (see Note 11). Deferred revenues primarily represents unrecognized fees billed or collected for extended service arrangements. The deferred revenue balance at September 30, 2020 and December 31, 2019 was $55.8 million and $45.8 million, respectively. The short-term deferred revenue balance at September 30, 2020 and December 31, 2019 was $40.9 million and $33.7 million, respectively. We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income. Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the nine month period ended September 30, 2020 and 2019 were as follows (in millions): Nine Months Ended September 30, 2020 2019 Balance at beginning of period $ 9.0 $ 10.1 Provision for warranty 5.4 7.3 Actual warranty costs (6.1) (8.4) Balance at end of period $ 8.3 $ 9.0 Allowance for Doubtful Accounts We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. We review our exposure to accounts receivable and reserve for amounts if collectability is no longer reasonably assured based on an assessment of various factors including historical loss rates and expectations of forward-looking loss estimates. Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer. Changes in our allowance for doubtful accounts were as follows (in millions): December 31, 2019 $ 20.2 Provision for expected credit losses 1.2 Write-offs charged against the allowance (2.1) Recoveries collected 0.1 September 30, 2020 $ 19.4 Implementation Costs for Cloud Computing Arrangements The balance of capitalized implementation costs for cloud computing arrangements, net of accumulated amortization, was $7.0 million and $3.1 million at September 30, 2020 and December 31, 2019, respectively. These costs were primarily for implementing business analytics software and were recorded in Other current assets and Other assets in the condensed consolidated balance sheets. Recent Accounting Pronouncements Adopted In May 2020, the SEC issued Final Rule Release No. 33-10786, "Amendments to Financial Disclosures About Acquired and Disposed Businesses" that amends financial statement requirements for acquisitions and dispositions of businesses, and related pro forma financial information. Among other changes, the final rule modifies the significance tests and improves disclosure requirements. We early adopted this final rule as of April 1, 2020, which did not have a material effect on our condensed consolidated financial statements. In March 2020, the FASB issued ASU No. 2020-04, "Facilitation of the Effects of Reference Rate Reform on Financial Reporting (Topic 848)" The ASU provides optional expedients and exceptions for applying GAAP to transactions affected by reference rate (e.g., LIBOR) reform if certain criteria are met, for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The ASU is effective as of March 12, 2020 through December 31, 2022. We will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. The ASU is currently not expected to have a material impact on our condensed consolidated financial statements. In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurements," which aims to improve the overall usefulness of disclosures to financial statement users and reduce unnecessary costs to companies when preparing fair value measurement disclosures. We adopted this standard effective January 1, 2020, which did not have a material impact on our condensed consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 replaces the incurred loss approach with an expected loss model for instruments measured at amortized cost and requires entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount as done under the former other-than-temporary impairment model. We adopted ASU 2016-13 as of January 1, 2020 using the cumulative effect transition method. We have evaluated our impacted instruments for credit quality indicators, and have determined that there is no cumulative effect transition adjustment to retained earnings as of our adoption date. ASU 2016-13 had an insignificant impact to our condensed consolidated financial statements for the nine months ended September 30, 2020. See also Note 3, Fair Value Measurements, and the section above under the caption “Allowance for Doubtful Accounts.” Recent Accounting Pronouncements to be Adopted In January 2020, the FASB issued ASU 2020-01, "Clarifying the Interactions between Topic 321 Investments—Equity Securities, Topic 323 Investments—Equity Method and Joint Ventures, and Topic 815 Derivatives and Hedging." ASU 2020-01 clarifies that a company should consider observable transactions that require a company to either apply or discontinue the equity method of accounting under Topic 323 for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method. ASU 2020-01 also clarifies that, when determining the accounting for certain forward contracts and purchased options a company should not consider, whether upon settlement or exercise, if the underlying securities would be accounted for under the equity method or fair value option. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020. Early adoption is permitted, including interim periods for which financial statements have not been issued. We are currently evaluating the effect of ASU 2020-01. In December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes," which eliminates certain exceptions within ASC 740, Income Taxes , and clarifies other aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020 and early adoption is permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. We are currently evaluating the effect of adopting this pronouncement on our financial statements and disclosures. In August 2018, the FASB issued ASU 2018-14, "Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans." ASU 2018-14 eliminates and adds certain disclosures for defined benefit plans. ASU 2018-14 is effective for fiscal years ending after December 15, 2020 using a retrospective approach. Early adoption is permitted. We are currently evaluating the disclosures but do not expect ASU 2018-14 to have a material impact to our disclosures for defined benefit plans.

2. Acquisitions (Notes)

2. Acquisitions (Notes)	9 Months Ended
	Sep. 30, 2020
Business Combinations [Abstract]
Mergers, Acquisitions and Dispositions Disclosures	ACQUISITIONS AND DIVESTITURES ACQUISITIONS Celsee Acquisition: On April 1, 2020 (the "Acquisition Date"), we acquired all equity interests of Celsee, Inc. ("Celsee") for total consideration of $99.3 million (as described in the table below), including the estimated fair value of contingent consideration. The contingent consideration of up to $60.0 million is payable in cash, upon the achievement of certain net revenues for the period beginning on January 1, 2021 and ending on December 31, 2022. Celsee is a manufacturer of instruments and consumables for the isolation, detection, and analysis of single cells. We believe this acquisition will complement our Life Science product offerings. The acquisition was included in our Life Science segment's results of operations from the Acquisition Date. Celsee met the definition of a business, and therefore is accounted for as a business combination. The fair value of consideration transferred for the Celsee acquisition consists of the following (in millions): Purchase price (cash) $ 99.2 Fair value of contingent consideration (earn-out) 0.1 Fair value of total consideration transferred $ 99.3 The following table summarizes the final fair values of the assets acquired and liabilities assumed at the Acquisition Date (in millions): Fair Value Cash and cash equivalents $ 0.6 Intangible assets 79.9 Deferred tax assets 8.4 Deferred tax liabilities (19.7) Other identifiable assets acquired, net 0.3 Net identifiable assets acquired 69.5 Goodwill 29.8 Net assets acquired $ 99.3 Goodwill related to the acquisition is primarily attributable to opportunities and economies of scale from combining the operations and technologies of Bio-Rad and Celsee, and is not deductible for tax purposes. The following table summarizes the final fair values and estimated useful lives of the components of identifiable intangible assets acquired as of the Acquisition Date (in millions): Fair Value Estimated Useful Life (years) Developed product technology $ 70.3 18.9 Customer relationships 3.6 4.0 Covenants not to compete 1.4 3.0 In-process research and development 4.6 Total identifiable intangible assets acquired $ 79.9 Intangible assets acquired as a result of the Celsee acquisition are being amortized over their estimated useful lives using the straight-line method of amortization, which materially approximates the distribution of the economic value of the identified intangible assets. Amortization of acquired developed technology of $0.9 million and $1.8 million for the three and nine months ended September 30, 2020, respectively, are included in Cost of goods sold in the condensed consolidated statements of income. Amortization of the acquired customer relationships of $0.2 million and $0.4 million and covenants not to compete of $0.1 million and $0.2 million for the three and nine months ended September 30, 2020, respectively, are included in Selling, general and administrative expense in the condensed consolidated statements of income. In-process research and development (IPR&D) is accounted for as an indefinite-lived asset. Once the project is completed, the carrying value of the IPR&D will be amortized over the estimated useful life of the asset. IPR&D is assessed for impairment on an annual basis until the project is completed. We believe the values of acquired intangible assets reported above represent their fair values and approximate the amounts a market participant would pay for these intangible assets as of the Acquisition Date. The final allocation of the payments reflects the effects of working capital and deferred tax adjustments made during the measurement period. These adjustments resulted in a $0.3 million decrease in deferred tax assets, a $0.4 million increase in goodwill and a $0.3 million increase in deferred tax liabilities compared to the preliminary balances reported at June 30, 2020 and had no impact on our condensed consolidated statements of income, for the three and nine months ended September 30, 2020. We included Celsee's fair value of assets acquired and liabilities assumed in our condensed consolidated balance sheets beginning on the Acquisition Date. The results of operations for Celsee subsequent to the Acquisition Date have been included in, but are immaterial to, our condensed consolidated statements of income for the three and nine months ended September 30, 2020. Pro forma results of operations for the Celsee acquisition have not been presented because they are not material to the condensed consolidated statements of income. Distributor Acquisition: In October 2019, we acquired all the issued and outstanding shares of a foreign distributor for approximately $4.2 million, which included cash payments at closing, net of closing cash, of $3.6 million, and $0.6 million in contingent consideration potentially payable to the sellers. In addition, we recorded a net gain of $0.4 million for the settlement of preexisting conditions concurrent with the acquisition that was recorded in Selling, general and administrative expense. The acquisition was included in our Clinical Diagnostics segment's results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. Pro forma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented. The final allocation of the payments was $3.4 million to customer relationships, a definite-lived intangible, $0.2 million to deferred tax asset, $0.8 million to deferred tax liability related to the purchased intangible and $1.4 million to acquired net assets. The final allocation of payments was unchanged from our preliminary allocation for the period ended December 31, 2019. DIVESTITURE Informatics Divestiture: In April 2020, we received $12.2 million for the sale of our Informatics division, which focused on providing and developing comprehensive, high-quality spectral databases and associated software. The division was part of our Other Operations segment. In connection with this sale, we recorded an $11.7 million gain in Other income, net, in the condensed consolidated statements of income for the nine months ended September 30, 2020.

3. Fair Value Measurements

3. Fair Value Measurements	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows: • Level 1: Quoted prices in active markets for identical instruments • Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments) • Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments) Financial assets and liabilities carried at fair value and measured on a recurring basis as of September 30, 2020 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 108.8 $ — $ 108.8 Asset-backed securities — 0.1 — 0.1 U.S. government sponsored agencies — 71.6 — 71.6 Time deposits 14.6 10.0 — 24.6 Money market funds 127.1 — — 127.1 Total cash equivalents (a) 141.7 190.5 — 332.2 Restricted investments (b) 6.6 — — 6.6 Equity securities (c) 8,459.3 — — 8,459.3 Available-for-sale investments: Corporate debt securities — 114.4 — 114.4 U.S. government sponsored agencies — 78.2 — 78.2 Foreign government obligations — 5.0 — 5.0 Other foreign obligations — 2.1 — 2.1 Municipal obligations — 13.4 — 13.4 Asset-backed securities — 48.2 — 48.2 Total available-for-sale investments (d) — 261.3 — 261.3 Forward foreign exchange contracts (e) — 0.6 — 0.6 Total financial assets carried at fair value $ 8,607.6 $ 452.4 $ — $ 9,060.0 Financial liabilities carried at fair value: Forward foreign exchange contracts (f) $ — $ 1.3 $ — $ 1.3 Contingent consideration (g) — — 2.3 2.3 Total financial liabilities carried at fair value $ — $ 1.3 $ 2.3 $ 3.6 Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2019 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 42.9 $ — $ 42.9 Time deposits 31.2 10.0 — 41.2 Asset-backed securities — 0.1 — 0.1 Money market funds 69.9 — — 69.9 Total cash equivalents (a) 101.1 53.0 — 154.1 Restricted investments (b) 5.6 — — 5.6 Equity securities (c) 4,664.4 — — 4,664.4 Available-for-sale investments: Corporate debt securities — 204.5 — 204.5 U.S. government sponsored agencies — 106.1 — 106.1 Foreign government obligations — 4.7 — 4.7 Other foreign obligations — 3.1 — 3.1 Municipal obligations — 11.6 — 11.6 Asset-backed securities — 72.9 — 72.9 Total available-for-sale investments (d) — 402.9 — 402.9 Forward foreign exchange contracts (e) — 0.9 — 0.9 Total financial assets carried at fair value $ 4,771.1 $ 456.8 $ — $ 5,227.9 Financial liabilities carried at fair value: Forward foreign exchange contracts (f) $ — $ 1.0 $ — $ 1.0 Contingent consideration (g) — — 4.9 4.9 Total financial liabilities carried at fair value $ — $ 1.0 $ 4.9 $ 5.9 (a) Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets. (b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions): September 30, 2020 December 31, 2019 Restricted investments $ 5.6 $ 5.6 Other investments 1.0 — Total $ 6.6 $ 5.6 (c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions): September 30, 2020 December 31, 2019 Short-term investments $ 53.0 $ 51.0 Other investments 8,406.3 4,613.4 Total $ 8,459.3 $ 4,664.4 The unrealized gains on our equity securities for the three and nine months ended September 30, 2020 were $1,580.3 million and $3,591.5 million, respectively, and were primarily due to our investment in Sartorius AG and are recorded in our condensed consolidated statements of income. As of September 30, 2020, we own 12,987,900 ordinary voting shares and 9,588,908 preferenc e shares of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own approximately 37% of the ordinary outstanding voting shares (excluding treasury shares) and 28% of the preference shares of Sartorius as of September 30, 2020. The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius' board of directors, nor do we have the ability to exercise significant influence over the operating and financial policies of Sartorius. (d) Available-for-sale investments are included in the following accounts in the condensed consolidated balance sheets (in millions): September 30, 2020 December 31, 2019 Short-term investments $ 261.2 $ 402.8 Other investments 0.1 0.1 Total $ 261.3 $ 402.9 (e) Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets. (f) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets. (g) Contingent consideration liability is included in the following accounts in the condensed consolidated balance sheets (in millions): September 30, 2020 December 31, 2019 Other current liabilities $ 2.2 $ 3.3 Other long-term liabilities 0.1 1.6 Total $ 2.3 $ 4.9 During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel Labs. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2017 through 2020. The sales milestones could potentially range from $0 to an unlimited amount. In the first and third quarters of 2020, we paid $1.3 million and $0.4 million per the purchase agreement. The contingent consideration was accrued at its estimated fair value of $1.6 million as of September 30, 2020. During the fourth quarter of 2019, we recognized a contingent consideration liability for earn-out targets related to our acquisition of a foreign distributor. The first earn-out payment of $0.7 million was paid by the acquisition date and the remaining payment is due in the second half of 2020. The maximum earn-out payment due is $1.4 million. The contingent consideration was accrued at its estimated fair value of $0.6 million as of September 30, 2020. During the second quarter of 2020, we recognized a contingent consideration liability upon our acquisition of Celsee, Inc. which represents the future potential earn-out payments of up to $60.0 million payable in cash upon the achievement of certain net revenues for the period beginning on January 1, 2021 and ending on December 31, 2022. The fair value of the earn-out as of the Acquisition Date was approximately $0.1 million which was determined by using a Black-Scholes-Merton option-pricing valuation model that includes significant assumptions and unobservable inputs such as the projected revenues of Celsee over the earn-out period and the probability of the earn-out threshold being met. The fair value of the contingent consideration is remeasured at each reporting period based on the assumptions and inputs on the date of remeasurement. The fair value of the earn-out was approximately $0.1 million as of September 30, 2020. The following table provides a reconciliation of the Level 3 contingent consideration liabilities measured at estimated fair value (in millions): December 31, 2019 $ 4.9 Analytical flow cytometer platform: Payment of sales milestone (1.7) Decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense (1.0) Foreign distributor: Change in estimated fair value of contingent consideration included in Selling, general and administrative expense — Celsee, Inc.: Fair value of contingent consideration 0.1 September 30, 2020 $ 2.3 To estimate the fair value of Level 2 debt securities as of September 30, 2020, our primary pricing provider uses Reuters as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Reuters does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source. Available-for-sale investments consist of the following (in millions): September 30, 2020 Amortized Unrealized Unrealized Allowances for Credit Losses Short-term investments: Corporate debt securities $ 111.5 $ 2.9 $ — $ — $ 114.4 Municipal obligations 13.2 0.2 — — 13.4 Asset-backed securities 47.8 0.4 (0.1) — 48.1 U.S. government sponsored agencies 75.6 2.6 — — 78.2 Foreign government obligations 4.9 0.1 — — 5.0 Other foreign obligations 2.1 — — — 2.1 255.1 6.2 (0.1) — 261.2 Long-term investments: Asset-backed securities 0.1 — — — 0.1 0.1 — — — 0.1 Total $ 255.2 $ 6.2 $ (0.1) $ — $ 261.3 The following is a summary of the amortized cost and estimated fair value of our debt securities at September 30, 2020 by contractual maturity date (in millions): Amortized Estimated Fair Mature in less than one year $ 95.0 $ 95.7 Mature in one to five years 113.5 116.4 Mature in more than five years 46.7 49.2 Total $ 255.2 $ 261.3 Available-for-sale investments consist of the following (in millions): December 31, 2019 Amortized Unrealized Unrealized Estimated Short-term investments: Corporate debt securities $ 203.2 $ 1.4 $ (0.1) $ 204.5 Municipal obligations 11.5 0.1 — 11.6 Asset-backed securities 72.7 0.2 (0.1) 72.8 U.S. government sponsored agencies 105.6 0.7 (0.2) 106.1 Foreign government obligations 4.7 — — 4.7 Other foreign obligations 3.1 — — 3.1 400.8 2.4 (0.4) 402.8 Long-term investments: Asset-backed securities 0.1 — — 0.1 0.1 — — 0.1 Total $ 400.9 $ 2.4 $ (0.4) $ 402.9 The following is a summary of investments with gross unrealized losses and the associated fair value (in millions): September 30, 2020 Less than 12 months Greater than 12 months Total Description of securities: Fair Value Unrealized Losses Fair Value Unrealized Losses Fair Value Unrealized Losses Asset-backed securities 6.9 0.1 — — 6.9 0.1 Total $ 6.9 $ 0.1 $ — $ — $ 6.9 $ 0.1 December 31, 2019 Less than 12 months Greater than 12 months Total Description of securities: Fair Value Unrealized Losses Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 46.5 $ 0.1 $ 2.1 $ — $ 48.6 $ 0.1 Asset-backed securities 17.9 — 7.0 0.1 24.9 0.1 U.S government sponsored agencies 27.5 0.2 10.8 — 38.3 0.2 Total $ 91.9 $ 0.3 $ 19.9 $ 0.1 $ 111.8 $ 0.4 The unrealized losses of $0.1 million as of September 30, 2020 are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others. As outlined in Note 1, we adopted ASU 2016-13 as of January 1, 2020. ASU 2016-13 replaced the incurred loss approach with an expected loss model for instruments measured at amortized cost and requires entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount as done under the former other-than-temporary impairment model. The factors we considered in our evaluation included t he extent to which the fair value is less than the amortized cost basis, adverse conditions specifically related to the debt security, an industry or geographic area, and any changes in the rating of a security by a rating agency. Credit loss impairments are limited to the amount that the fair value of an instrument is less than its amortized cost basis. At September 30, 2020, we have concluded that all payments related to our available-for-sale investments are expected to be made in full and on time at par value. The diminution of value in the intervening period is due to market conditions such as illiquidity and interest rate movements and not due to significant, inherent credit concerns surrounding the issuer. As a result, we have no allowances for credit losses on our available-for-sale investments portfolio as of September 30, 2020. Included in Other current assets are $1.5 million and $2.0 million of interest receivable as of September 30, 2020 and December 31, 2019, respectively, primarily associated with securities in our available-for-sale investments portfolio. Associated interest on these securities is typically payable semi-annually. Due to the short-term nature of our interest receivable asset, we have made an accounting policy election not to measure an allowance for credit losses for accrued interest receivable. We consider any uncollected interest receivable that is overdue greater than one year to be impaired for purposes of write-off. For the three and nine months ended September 30, 2020, we have not written-off any uncollected interest receivable. As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date. The notional principal amounts provide one measure of the transaction volume outstanding as of September 30, 2020 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties. The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in Foreign currency exchange losses, net in the condensed consolidated statements of income. The following is a summary of our forward foreign exchange contracts (in millions): September 30, 2020 Contracts maturing in October through December 2020 to sell foreign currency: Notional value $ 75.6 Unrealized gain $ 0.1 Contracts maturing in October through December 2020 to purchase foreign currency: Notional value $ 272.4 Unrealized loss $ (0.9) The estimated fair value of our current maturities of long-term debt, excluding leases, as of September 30, 2020 and December 31, 2019 that is not recognized at fair value in the condensed consolidated balance sheets has an estimated fair value based on quoted market prices for the same or similar issues. The estimated fair value of our long-term debt and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions): September 30, 2020 December 31, 2019 Carrying Estimated Fair Value Hierarchy Level Carrying Estimated Fair Value Hierarchy Level Current maturities of long-term debt, excluding leases $ 424.9 $ 429.0 2 $ 424.4 $ 435.5 2

4. Intangible Assets, Goodwill

4. Intangible Assets, Goodwill and Other	9 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure	GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS Changes to goodwill by segment were as follows (in millions): Life Clinical Total Balances as of December 31, 2019: Goodwill $ 250.1 $ 349.2 $ 599.3 Accumulated impairment losses (41.8) (293.4) (335.2) Goodwill, net 208.3 55.8 264.1 Acquisitions (*) 29.8 — 29.8 Other adjustments (**) (2.0) — (2.0) Balances as of September 30, 2020: Goodwill 277.9 349.2 627.1 Accumulated impairment losses (41.8) (293.4) (335.2) Goodwill, net $ 236.1 $ 55.8 $ 291.9 * Acquisitions consist of $29.8 million recorded for Celsee, Inc. (see Note 2, "Acquisitions and Divestitures"). ** Goodwill decreased by $2.0 million due to the release from an escrow account setup during our acquisition of a small U.S. private company, which should have been classified as a prepaid asset in its opening balance sheet as of the March 2, 2019 acquisition date. Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions): September 30, 2020 Weighted-Average Remaining Amortization Period (years) Purchase Accumulated Net Customer relationships/lists 5.68 $ 112.8 $ (81.9) $ 30.9 Know how 5.00 192.6 (170.3) 22.3 Developed product technology 14.21 215.3 (102.2) 113.1 Licenses 7.99 65.2 (36.2) 29.0 Tradenames 7.99 6.5 (4.0) 2.5 Covenants not to compete 4.08 4.5 (1.8) 2.7 Other — 0.1 (0.1) — Total definite-lived intangible assets 597.0 (396.5) 200.5 In-process research and development 4.8 — 4.8 Total purchased intangible assets $ 601.8 $ (396.5) $ 205.3 December 31, 2019 Weighted-Average Remaining Amortization Period (years) Purchase Accumulated Net Customer relationships/lists 6.36 $ 107.2 $ (74.3) $ 32.9 Know how 5.71 188.5 (162.6) 25.9 Developed product technology 8.31 144.2 (93.9) 50.3 Licenses 8.74 76.0 (44.4) 31.6 Tradenames 8.50 6.4 (3.6) 2.8 Covenants not to compete 6.01 3.2 (1.4) 1.8 Other — 0.1 (0.1) — Total definite-lived intangible assets 525.6 (380.3) 145.3 In-process research and development 0.2 — 0.2 Total purchased intangible assets $ 525.8 $ (380.3) $ 145.5 Amortization expense related to purchased intangible assets is as follows (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Amortization expense $ 7.2 $ 6.0 $ 20.3 $ 17.1

6. Long-Term Debt

6. Long-Term Debt	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Long-term Debt	LONG-TERM DEBT The principal components of long-term debt are as follows (in millions): September 30, December 31, 4.875% Senior Notes due 2020 principal amount $ 425.0 $ 425.0 Less unamortized discount and debt issuance costs (0.1) (0.6) 4.875% Senior Notes less unamortized discount and debt issuance costs 424.9 424.4 Finance leases and other debt 13.9 15.4 438.8 439.8 Less current maturities (426.6) (426.2) Long-term debt $ 12.2 $ 13.6 Senior Notes due 2020 In December 2010, Bio-Rad sold $425.0 million principal amount of Senior Notes due December 2020 (4.875% Notes). The sale yielded net cash proceeds of $422.6 million at an effective rate of 4.946%. The 4.875% Notes pay a fixed rate of interest of 4.875% per year. We have the option to redeem any or all of the 4.875% Notes at any time at a redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the indenture governing the 4.875% Notes) and accrued and unpaid interest thereon to the redemption date. Our obligations under the 4.875% Notes are not secured and rank equal in right of payment with all of our existing and future unsubordinated indebtedness. Certain covenants apply at each year end to the 4.875% Notes including limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. We were in compliance with these covenants as of September 30, 2020. There are no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios. Credit Agreement In April 2019, Bio-Rad entered into a $200.0 million unsecured revolving credit facility ("Credit Agreement"). Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of September 30, 2020; however, $0.2 million was utilized for domestic standby letters of credit that reduced our borrowing availability as of September 30, 2020. The Credit Agreement matures in April 2024. If we had borrowed against our Credit Agreement, the borrowing rate would have been 1.355% at September 30, 2020, which is based on the 3-month LIBOR. The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens. We were in compliance with all of these ratios and covenants as of September 30, 2020.

7. Accumulated Other Comprehens

7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Notes)	9 Months Ended
	Sep. 30, 2020
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Accumulated other comprehensive income included in our condensed consolidated balance sheets consists of the following components (in millions): Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains on available-for-sale investments Total accumulated other comprehensive income (loss) Balances as of January 1, 2020: $ (72.4) $ (22.2) $ 7.2 $ (87.4) Other comprehensive income (loss), before reclassifications 167.4 (1.3) 4.5 170.6 Amounts reclassified from Accumulated other comprehensive income — 1.8 (0.6) 1.2 Income tax effects — 0.4 (0.9) (0.5) Other comprehensive income, net of income taxes 167.4 0.9 3.0 171.3 Balances as of September 30, 2020: $ 95.0 $ (21.3) $ 10.2 $ 83.9 Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains on available-for-sale investments Total accumulated other comprehensive income (loss) Balances as of January 1, 2019: $ (35.5) $ (14.8) $ 3.3 $ (47.0) Other comprehensive (loss) income, before reclassifications (109.9) 0.1 5.1 (104.7) Amounts reclassified from Accumulated other comprehensive income — 0.6 (0.3) 0.3 Income tax effects — (0.2) (0.6) (0.8) Other comprehensive (loss) income, net of income taxes (109.9) 0.5 4.2 (105.2) Balances as of September 30, 2019: $ (145.4) $ (14.3) $ 7.5 $ (152.2) The reclassification adjustments are calculated using the specific identification method. The impact to income before taxes for amounts reclassified out of Accumulated other comprehensive income into the condensed consolidated statements of income, with presentation location, were as follows (in millions): Three Months Ended Nine Months Ended September 30, September 30, Components of Comprehensive income 2020 2019 2020 2019 Location Amortization of foreign other post-employment benefit items $ (1.1) $ (0.2) $ (1.8) $ (0.6) Other (income) expense, net Net holding gains on equity securities and available-for-sale investments $ — $ 0.2 $ 0.6 $ 0.3 Other (income) expense, net

8. Earnings Per Share

8. Earnings Per Share	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Earnings Per Share	. EARNINGS PER SHARE Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period. Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding. Potential common shares are excluded from the diluted earnings per share calculation if the effect of including such securities would be anti-dilutive. The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Basic weighted average shares outstanding 29,721 29,831 29,746 29,815 Effect of potentially dilutive stock options and restricted stock awards 407 — 391 334 Diluted weighted average common shares 30,128 29,831 30,137 30,149 Anti-dilutive shares 41 95 17 56

9. Other Income and Expenses

9. Other Income and Expenses	9 Months Ended
	Sep. 30, 2020
Other Income and Expenses [Abstract]
Other Income and Other Expense Disclosure	. OTHER INCOME AND EXPENSE, NET Other (income) expense, net includes the following components (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Interest and investment income $ (1.8) $ (4.1) $ (14.6) $ (27.4) Net realized gains on investments — (0.2) (0.6) (0.2) Other-than-temporary impairment losses on investments — — 4.6 1.6 Gain on divestiture of a division — — (11.7) — Other expense (income) 0.8 (0.1) 0.8 (1.0) Other (income), net $ (1.0) $ (4.4) $ (21.5) $ (27.0)

10. Income Taxes

10. Income Taxes	9 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	10. INCOME TAXES Our effective income tax rate was 21.9% and 22.8% for the three months ended September 30, 2020 and 2019, respectively. Our effective income tax rate was 22.5% and 22.8% for the nine months ended September 30, 2020 and 2019, respectively. The realization of deferred tax assets is dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that our California and certain foreign deferred tax assets will not be realized as of September 30, 2020, and have maintained a valuation allowance on such deferred tax assets. Our income tax returns are routinely audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues around the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period. Our gross unrecognized tax benefits were $54.4 million and $39.2 million as of September 30, 2020 and December 31, 2019, respectively. The net increase to our gross unrecognized tax benefits is primarily the result of a $13.3 million reassessment of a tax position taken in a prior period as a result of new information obtained during the current year. As of September 30, 2020, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitations for certain jurisdictions, we believe that within the next 12 months it is reasonably possible that our previously unrecognized tax benefits could decrease by up to $4.7 million primarily related to various foreign jurisdictions.

11. Segment Information Segment

11. Segment Information Segment Reporting	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	SEGMENT INFORMATION Information regarding operating segments for the three months ended September 30, 2020 and 2019 is as follows (in millions): Life Clinical Other Segment net sales 2020 $ 324.0 $ 322.2 $ 1.1 2019 $ 215.7 $ 341.8 $ 3.1 Segment net profit (loss) 2020 $ 70.3 $ 38.0 $ (0.8) 2019 $ 11.6 $ 43.8 $ (0.4) Information regarding operating segments for the nine months ended September 30, 2020 and 2019 is as follows (in millions): Life Clinical Other Segment net sales 2020 $ 803.2 $ 945.6 $ 7.0 2019 $ 643.9 $ 1,032.9 $ 10.4 Segment net profit (loss) 2020 $ 128.3 $ 100.9 $ (0.2) 2019 $ 45.9 $ 117.1 $ (1.1) Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. Net corporate operating and other expense for segment results consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker. Interest expense is charged to segments based on the carrying amount of inventory and receivables employed by that segment. The following reconciles total segment profit to consolidated income before income taxes (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Total segment profit $ 107.5 $ 55.0 $ 229.0 $ 161.9 Foreign currency exchange losses, net (0.8) (0.9) (2.5) (3.4) Net corporate operating and other expense not allocated to segments (3.6) (3.1) (10.4) (8.8) Change in fair market value of equity securities 1,580.4 (390.6) 3,591.5 1,385.0 Other income, net 1.0 4.4 21.5 27.0 Consolidated income (loss) before income taxes $ 1,684.5 $ (335.2) $ 3,829.1 $ 1,561.7

12. Legal Proceedings

12. Legal Proceedings	9 Months Ended
	Sep. 30, 2020
Loss Contingency, Information about Litigation Matters [Abstract]
Legal Proceedings.	12. LEGAL PROCEEDINGS We are a party to various claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.

13. Restructuring Costs (Notes)

13. Restructuring Costs (Notes)	9 Months Ended
	Sep. 30, 2020
Restructuring Costs [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	RESTRUCTURING COSTS In December 2018, we announced the closure of a small manufacturing facility in France. Restructuring charges for the facility closure are included in our Clinical Diagnostics segment's results of operations. The liability of $1.9 million as of September 30, 2020 was recorded in Accrued payroll and employee benefits in the condensed consolidated balance sheets. From December 2018 to September 30, 2020, total expenses were $4.0 million The following table summarizes the activity for the facility closure restructuring reserves for severance and exit costs (in millions): Balances as of December 31, 2019: $ 3.2 Cash payments (1.4) Foreign currency translation losses 0.1 Balances as of September 30, 2020: $ 1.9 In November 2019, we announced our strategy-driven restructuring plan. We expect that a significant portion of the net savings resulting from this restructuring plan will be repurposed in alignment with our portfolio strategy. The restructuring plan includes a workforce reduction in Europe, the United States and Canada, and is expected to be incurred through 2020. The liability of $6.8 million as of September 30, 2020 was recorded in Accrued payroll and employee benefits in the condensed consolidated balance sheets. The amounts reflected in Cost of goods sold, Selling, general and administrative expense and Research and development expense were $(1.0) million and $(4.5) million in the condensed consolidated statements of income for the three and nine months ended September 30, 2020, respectively. From November 2019 to September 30, 2020, total expenses were $20.8 million. The following table summarizes the activity of our European and North American reorganization restructuring reserves for severance (in millions): Life Science Clinical Diagnostics Total Balances as of December 31, 2019: $ 6.2 $ 19.1 $ 25.3 Adjustment to expense (0.6) (3.9) (4.5) Cash payments (3.8) (10.5) (14.3) Foreign currency translation losses — 0.3 0.3 Balances as of September 30, 2020: $ 1.8 $ 5.0 $ 6.8 In June 2020, we announced a restructuring plan to consolidate certain finance and administrative activities in Europe and the United States. The restructuring plan is expected to be completed by March 2021. The liability of $3.1 million as of September 30, 2020 was recorded in Accrued payroll and employee benefits in the condensed consolidated balance sheets. The amounts reflected in Selling, general and administrative expense were $(0.2) million and $3.6 million for the three and nine months ended September 30, 2020, respectively. The following table summarizes the restructuring activities related to the finance and administrative reorganization (in millions): Life Science Clinical Diagnostics Total Balances as of December 31, 2019: $ — $ — $ — Charged to expense 1.5 2.3 3.8 Adjustment to expense (0.1) (0.1) (0.2) Cash payments (0.2) (0.3) (0.5) Balances as of September 30, 2020: $ 1.2 $ 1.9 $ 3.1

14. Leases (Notes)

14. Leases (Notes)	9 Months Ended
	Sep. 30, 2020
14. Leases [Abstract]
Leases Of Lessee	14. LEASES: FINANCE, AND OPERATING WHERE WE ACT AS LESSEE For operating leases where we act as lessor in reagent rental agreements, see Note 1. We have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. For operating leases, we have elected not to separate lease and non-lease components for buildings, vehicles and equipment. Our leases have remaining lease terms of 1 year to 19 years, which includes our determination to exercise renewal options. We determine if an arrangement is a lease at inception. Right-of-use (ROU) assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Operating lease ROU assets also include any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The components of lease expense were as follows (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Operating lease cost $ 13.4 $ 14.2 $ 38.4 $ 38.7 Finance lease cost: Amortization of right-of-use assets $ 0.1 $ 0.1 $ 0.4 $ 0.5 Interest on lease liabilities 0.2 0.2 0.6 0.7 Total finance lease cost $ 0.3 $ 0.3 $ 1.0 $ 1.2 Sublease income $ 0.7 $ 0.7 $ 2.2 $ 2.2 The sublease is for a building with a term that ends in 2025, with no options to extend or renew. Operating lease cost includes original reduction in the carrying amount of ROU assets, the impact of remeasurements, modifications, impairments and abandonments. Our short-term leases are expensed as incurred, reflecting leases with a lease term of one year or less, and are not significant for both the three and nine months ended September 30, 2020 and 2019. Operating lease variable cost is primarily comprised of reimbursed actual common area maintenance, property taxes and insurance, which are immaterial for both the three and nine months ended September 30, 2020 and 2019. Supplemental cash flow information related to leases was as follows (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 10.8 $ 11.6 $ 33.0 $ 34.5 Operating cash flows from finance leases $ 0.1 $ 0.2 $ 0.4 $ 0.7 Financing cash flows from finance leases $ 0.2 $ 0.1 $ 0.6 $ 0.5 Right-of-use assets obtained in exchange for new lease obligations: Operating leases $ 0.8 $ 14.4 $ 8.4 $ 20.2 Finance leases $ 0.1 $ 0.1 $ 0.2 $ 0.1 Supplemental balance sheet information related to leases was as follows (in millions): September 30, 2020 December 31, 2019 Operating Leases Operating lease right-of-use assets $ 196.7 $ 201.9 Current operating lease liabilities $ 34.4 $ 35.4 Operating lease liabilities 172.1 176.0 Total operating lease liabilities $ 206.5 $ 211.4 Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities. September 30, 2020 December 31, 2019 Finance Leases Property, plant and equipment, gross $ 11.7 $ 11.4 Less: accumulated depreciation and amortization (4.6) (4.2) Property, plant and equipment, net $ 7.1 $ 7.2 Current maturities of long-term debt and notes payable $ 0.5 $ 0.5 Long-term debt, net of current maturities 11.1 11.2 Total finance lease liabilities $ 11.6 $ 11.7 September 30, 2020 December 31, 2019 Weighted Average Remaining Lease Term Operating leases - in years 9 9 Finance leases - in years 17 18 Weighted Average Discount Rate Operating leases 4.0 % 4.2 % Finance leases 6.5 % 6.5 % Maturities of lease liabilities were as follows (in millions): Year Ending December 31, Operating Leases Finance Leases 2020 (excluding the nine months ended September 30, 2020) $ 10.8 $ 1.2 2021 41.1 1.2 2022 33.8 1.1 2023 28.7 1.1 2024 24.8 1.1 Thereafter 111.5 13.3 Total lease payments 250.7 19.0 Less imputed interest (44.2) (7.4) Total $ 206.5 $ 11.6

1. Basis of Presentation and _2

1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Policies)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. We review our exposure to accounts receivable and reserve for amounts if collectability is no longer reasonably assured based on an assessment of various factors including historical loss rates and expectations of forward-looking loss estimates. Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer. Changes in our allowance for doubtful accounts were as follows (in millions): December 31, 2019 $ 20.2 Provision for expected credit losses 1.2 Write-offs charged against the allowance (2.1) Recoveries collected 0.1 September 30, 2020 $ 19.4
Standard Product Warranty, Policy [Policy Text Block]	We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income. Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the nine month period ended September 30, 2020 and 2019 were as follows (in millions): Nine Months Ended September 30, 2020 2019 Balance at beginning of period $ 9.0 $ 10.1 Provision for warranty 5.4 7.3 Actual warranty costs (6.1) (8.4) Balance at end of period $ 8.3 $ 9.0
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Adopted In May 2020, the SEC issued Final Rule Release No. 33-10786, "Amendments to Financial Disclosures About Acquired and Disposed Businesses" that amends financial statement requirements for acquisitions and dispositions of businesses, and related pro forma financial information. Among other changes, the final rule modifies the significance tests and improves disclosure requirements. We early adopted this final rule as of April 1, 2020, which did not have a material effect on our condensed consolidated financial statements. In March 2020, the FASB issued ASU No. 2020-04, "Facilitation of the Effects of Reference Rate Reform on Financial Reporting (Topic 848)" The ASU provides optional expedients and exceptions for applying GAAP to transactions affected by reference rate (e.g., LIBOR) reform if certain criteria are met, for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The ASU is effective as of March 12, 2020 through December 31, 2022. We will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. The ASU is currently not expected to have a material impact on our condensed consolidated financial statements. In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurements," which aims to improve the overall usefulness of disclosures to financial statement users and reduce unnecessary costs to companies when preparing fair value measurement disclosures. We adopted this standard effective January 1, 2020, which did not have a material impact on our condensed consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 replaces the incurred loss approach with an expected loss model for instruments measured at amortized cost and requires entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount as done under the former other-than-temporary impairment model. We adopted ASU 2016-13 as of January 1, 2020 using the cumulative effect transition method. We have evaluated our impacted instruments for credit quality indicators, and have determined that there is no cumulative effect transition adjustment to retained earnings as of our adoption date. ASU 2016-13 had an insignificant impact to our condensed consolidated financial statements for the nine months ended September 30, 2020. See also Note 3, Fair Value Measurements, and the section above under the caption “Allowance for Doubtful Accounts.” Recent Accounting Pronouncements to be Adopted In January 2020, the FASB issued ASU 2020-01, "Clarifying the Interactions between Topic 321 Investments—Equity Securities, Topic 323 Investments—Equity Method and Joint Ventures, and Topic 815 Derivatives and Hedging." ASU 2020-01 clarifies that a company should consider observable transactions that require a company to either apply or discontinue the equity method of accounting under Topic 323 for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method. ASU 2020-01 also clarifies that, when determining the accounting for certain forward contracts and purchased options a company should not consider, whether upon settlement or exercise, if the underlying securities would be accounted for under the equity method or fair value option. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020. Early adoption is permitted, including interim periods for which financial statements have not been issued. We are currently evaluating the effect of ASU 2020-01. In December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes," which eliminates certain exceptions within ASC 740, Income Taxes , and clarifies other aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020 and early adoption is permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. We are currently evaluating the effect of adopting this pronouncement on our financial statements and disclosures. In August 2018, the FASB issued ASU 2018-14, "Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans." ASU 2018-14 eliminates and adds certain disclosures for defined benefit plans. ASU 2018-14 is effective for fiscal years ending after December 15, 2020 using a retrospective approach. Early adoption is permitted. We are currently evaluating the disclosures but do not expect ASU 2018-14 to have a material impact to our disclosures for defined benefit plans.
Revenue from Contract with Customer [Policy Text Block]		Revenue Recognition We recognize revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment, and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recognized until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to customer specifications, which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control in relation to the equipment has occurred at that point as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon customer acceptance because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service. At the time revenue is recognized, a provision is recorded for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, the transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used to determine the stand-alone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance. We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant. Reagent Rental Agreements Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we next must ascertain its lease classification for purposes of applying appropriate accounting treatment as an operating, sales-type or direct financing lease. For purposes of determining the lease term used in performing the lease classification test, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if the customer is reasonably certain to exercise that option, the periods covered by an option to terminate the lease if the customer is reasonably certain not to exercise that option, and the periods covered by the option to extend (or not to terminate) the lease in which exercise of the option is controlled by the Company. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel, the period in which the contract is enforceable is a very short period and therefore the lease term has been limited to the noncancellable period. Generally these arrangements do not contain an option for the lessee to purchase the underlying asset. We concluded that the use of the instrument (referred to as “lease elements”) is not within the guidance of ASC 606 but rather ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After allocation, the amount of variable payments allocated to lease components will be recognized as income under ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Upon our adoption of ASC 842 in 2019, the maintenance services, along with the reagents, are now allocated to the non-lease elements and will be recognized as income in accordance with ASC 606. This change is in accordance with the requirements of ASC 842, and has resulted in a decrease in the amount of rental income and a corresponding increase in the amount of maintenance service revenue that is included in Net sales in our condensed consolidated statements of income. Generally, the terms of the arrangements result in the transfer of control for reagents upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer. Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as very few of such arrangements contain any fixed/minimum lease payments. Further, our reagent rental arrangements are predominantly classified as operating leases, and any sales-type leases represent in aggregate an immaterial amount of lease income. Our reported lease income is primarily variable in nature and is recognized upon delivery or as the reagents are consumed by the customer. Revenue allocated to the lease elements of these reagent rental arrangements represents approximately 3% of total revenue for both the three and nine months ended September 30, 2020, and September 30, 2019, and is included as part of Net sales in our condensed consolidated statements of income. Contract costs: As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income. Disaggregation of Revenue: The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Europe $ 220.9 $ 181.9 $ 590.6 $ 556.1 Asia 142.0 120.7 382.3 354.3 United States 250.4 225.8 685.4 674.0 Other (primarily Canada and Latin America) 34.0 32.2 97.5 102.8 Total net sales $ 647.3 $ 560.6 $ 1,755.8 $ 1,687.2 The disaggregation of our revenue by industry segment sources is presented in our Segment Information footnote (see Note 11).
Accounts Receivable, Allowance for Credit Loss [Table Text Block]	Changes in our allowance for doubtful accounts were as follows (in millions): December 31, 2019 $ 20.2 Provision for expected credit losses 1.2 Write-offs charged against the allowance (2.1) Recoveries collected 0.1 September 30, 2020 $ 19.4

1. Basis of Presentation and _3

1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables)	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Revenue from External Customers by Geographic Areas [Table Text Block]	The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Europe $ 220.9 $ 181.9 $ 590.6 $ 556.1 Asia 142.0 120.7 382.3 354.3 United States 250.4 225.8 685.4 674.0 Other (primarily Canada and Latin America) 34.0 32.2 97.5 102.8 Total net sales $ 647.3 $ 560.6 $ 1,755.8 $ 1,687.2
Schedule of Product Warranty Liability [Table Text Block]	Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the nine month period ended September 30, 2020 and 2019 were as follows (in millions): Nine Months Ended September 30, 2020 2019 Balance at beginning of period $ 9.0 $ 10.1 Provision for warranty 5.4 7.3 Actual warranty costs (6.1) (8.4) Balance at end of period $ 8.3 $ 9.0
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. We review our exposure to accounts receivable and reserve for amounts if collectability is no longer reasonably assured based on an assessment of various factors including historical loss rates and expectations of forward-looking loss estimates. Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer. Changes in our allowance for doubtful accounts were as follows (in millions): December 31, 2019 $ 20.2 Provision for expected credit losses 1.2 Write-offs charged against the allowance (2.1) Recoveries collected 0.1 September 30, 2020 $ 19.4

Business Combinations (Tables)

Business Combinations (Tables)	3 Months Ended
	Sep. 30, 2020
Business Combinations [Abstract]
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination	The following table summarizes the final fair values and estimated useful lives of the components of identifiable intangible assets acquired as of the Acquisition Date (in millions): Fair Value Estimated Useful Life (years) Developed product technology $ 70.3 18.9 Customer relationships 3.6 4.0 Covenants not to compete 1.4 3.0 In-process research and development 4.6 Total identifiable intangible assets acquired $ 79.9
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes the final fair values of the assets acquired and liabilities assumed at the Acquisition Date (in millions): Fair Value Cash and cash equivalents $ 0.6 Intangible assets 79.9 Deferred tax assets 8.4 Deferred tax liabilities (19.7) Other identifiable assets acquired, net 0.3 Net identifiable assets acquired 69.5 Goodwill 29.8 Net assets acquired $ 99.3
Schedule of Business Acquisitions, by Acquisition	The fair value of consideration transferred for the Celsee acquisition consists of the following (in millions): Purchase price (cash) $ 99.2 Fair value of contingent consideration (earn-out) 0.1 Fair value of total consideration transferred $ 99.3

3. Fair Value Measurements (Tab

3. Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Debt Securities, Available-for-sale [Table Text Block]	Available-for-sale investments consist of the following (in millions): September 30, 2020 Amortized Unrealized Unrealized Allowances for Credit Losses Short-term investments: Corporate debt securities $ 111.5 $ 2.9 $ — $ — $ 114.4 Municipal obligations 13.2 0.2 — — 13.4 Asset-backed securities 47.8 0.4 (0.1) — 48.1 U.S. government sponsored agencies 75.6 2.6 — — 78.2 Foreign government obligations 4.9 0.1 — — 5.0 Other foreign obligations 2.1 — — — 2.1 255.1 6.2 (0.1) — 261.2 Long-term investments: Asset-backed securities 0.1 — — — 0.1 0.1 — — — 0.1 Total $ 255.2 $ 6.2 $ (0.1) $ — $ 261.3	Available-for-sale investments consist of the following (in millions): December 31, 2019 Amortized Unrealized Unrealized Estimated Short-term investments: Corporate debt securities $ 203.2 $ 1.4 $ (0.1) $ 204.5 Municipal obligations 11.5 0.1 — 11.6 Asset-backed securities 72.7 0.2 (0.1) 72.8 U.S. government sponsored agencies 105.6 0.7 (0.2) 106.1 Foreign government obligations 4.7 — — 4.7 Other foreign obligations 3.1 — — 3.1 400.8 2.4 (0.4) 402.8 Long-term investments: Asset-backed securities 0.1 — — 0.1 0.1 — — 0.1 Total $ 400.9 $ 2.4 $ (0.4) $ 402.9
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a reconciliation of the Level 3 contingent consideration liabilities measured at estimated fair value (in millions): December 31, 2019 $ 4.9 Analytical flow cytometer platform: Payment of sales milestone (1.7) Decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense (1.0) Foreign distributor: Change in estimated fair value of contingent consideration included in Selling, general and administrative expense — Celsee, Inc.: Fair value of contingent consideration 0.1 September 30, 2020 $ 2.3
Summary of fair value of gross unrealized losses for investments with unrealized losses	The following is a summary of investments with gross unrealized losses and the associated fair value (in millions): September 30, 2020 Less than 12 months Greater than 12 months Total Description of securities: Fair Value Unrealized Losses Fair Value Unrealized Losses Fair Value Unrealized Losses Asset-backed securities 6.9 0.1 — — 6.9 0.1 Total $ 6.9 $ 0.1 $ — $ — $ 6.9 $ 0.1 December 31, 2019 Less than 12 months Greater than 12 months Total Description of securities: Fair Value Unrealized Losses Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 46.5 $ 0.1 $ 2.1 $ — $ 48.6 $ 0.1 Asset-backed securities 17.9 — 7.0 0.1 24.9 0.1 U.S government sponsored agencies 27.5 0.2 10.8 — 38.3 0.2 Total $ 91.9 $ 0.3 $ 19.9 $ 0.1 $ 111.8 $ 0.4
Discussion of current derivative risk management	The following is a summary of our forward foreign exchange contracts (in millions): September 30, 2020 Contracts maturing in October through December 2020 to sell foreign currency: Notional value $ 75.6 Unrealized gain $ 0.1 Contracts maturing in October through December 2020 to purchase foreign currency: Notional value $ 272.4 Unrealized loss $ (0.9)
Summary of amortized cost and estimated fair value of debt securities by contractual maturity date	The following is a summary of the amortized cost and estimated fair value of our debt securities at September 30, 2020 by contractual maturity date (in millions): Amortized Estimated Fair Mature in less than one year $ 95.0 $ 95.7 Mature in one to five years 113.5 116.4 Mature in more than five years 46.7 49.2 Total $ 255.2 $ 261.3
Estimated fair value of financial instruments	The estimated fair value of our long-term debt and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions): September 30, 2020 December 31, 2019 Carrying Estimated Fair Value Hierarchy Level Carrying Estimated Fair Value Hierarchy Level Current maturities of long-term debt, excluding leases $ 424.9 $ 429.0 2 $ 424.4 $ 435.5 2
Fair Value Measurements, Recurring and Nonrecurring	Financial assets and liabilities carried at fair value and measured on a recurring basis as of September 30, 2020 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 108.8 $ — $ 108.8 Asset-backed securities — 0.1 — 0.1 U.S. government sponsored agencies — 71.6 — 71.6 Time deposits 14.6 10.0 — 24.6 Money market funds 127.1 — — 127.1 Total cash equivalents (a) 141.7 190.5 — 332.2 Restricted investments (b) 6.6 — — 6.6 Equity securities (c) 8,459.3 — — 8,459.3 Available-for-sale investments: Corporate debt securities — 114.4 — 114.4 U.S. government sponsored agencies — 78.2 — 78.2 Foreign government obligations — 5.0 — 5.0 Other foreign obligations — 2.1 — 2.1 Municipal obligations — 13.4 — 13.4 Asset-backed securities — 48.2 — 48.2 Total available-for-sale investments (d) — 261.3 — 261.3 Forward foreign exchange contracts (e) — 0.6 — 0.6 Total financial assets carried at fair value $ 8,607.6 $ 452.4 $ — $ 9,060.0 Financial liabilities carried at fair value: Forward foreign exchange contracts (f) $ — $ 1.3 $ — $ 1.3 Contingent consideration (g) — — 2.3 2.3 Total financial liabilities carried at fair value $ — $ 1.3 $ 2.3 $ 3.6 Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2019 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 42.9 $ — $ 42.9 Time deposits 31.2 10.0 — 41.2 Asset-backed securities — 0.1 — 0.1 Money market funds 69.9 — — 69.9 Total cash equivalents (a) 101.1 53.0 — 154.1 Restricted investments (b) 5.6 — — 5.6 Equity securities (c) 4,664.4 — — 4,664.4 Available-for-sale investments: Corporate debt securities — 204.5 — 204.5 U.S. government sponsored agencies — 106.1 — 106.1 Foreign government obligations — 4.7 — 4.7 Other foreign obligations — 3.1 — 3.1 Municipal obligations — 11.6 — 11.6 Asset-backed securities — 72.9 — 72.9 Total available-for-sale investments (d) — 402.9 — 402.9 Forward foreign exchange contracts (e) — 0.9 — 0.9 Total financial assets carried at fair value $ 4,771.1 $ 456.8 $ — $ 5,227.9 Financial liabilities carried at fair value: Forward foreign exchange contracts (f) $ — $ 1.0 $ — $ 1.0 Contingent consideration (g) — — 4.9 4.9 Total financial liabilities carried at fair value $ — $ 1.0 $ 4.9 $ 5.9 (a) Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets. (b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions): September 30, 2020 December 31, 2019 Restricted investments $ 5.6 $ 5.6 Other investments 1.0 — Total $ 6.6 $ 5.6 (c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions): September 30, 2020 December 31, 2019 Short-term investments $ 53.0 $ 51.0 Other investments 8,406.3 4,613.4 Total $ 8,459.3 $ 4,664.4 The unrealized gains on our equity securities for the three and nine months ended September 30, 2020 were $1,580.3 million and $3,591.5 million, respectively, and were primarily due to our investment in Sartorius AG and are recorded in our condensed consolidated statements of income. As of September 30, 2020, we own 12,987,900 ordinary voting shares and 9,588,908 preferenc e shares of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own approximately 37% of the ordinary outstanding voting shares (excluding treasury shares) and 28% of the preference shares of Sartorius as of September 30, 2020. The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius' board of directors, nor do we have the ability to exercise significant influence over the operating and financial policies of Sartorius. (d) Available-for-sale investments are included in the following accounts in the condensed consolidated balance sheets (in millions): September 30, 2020 December 31, 2019 Short-term investments $ 261.2 $ 402.8 Other investments 0.1 0.1 Total $ 261.3 $ 402.9 (e) Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets. (f) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets. (g) Contingent consideration liability is included in the following accounts in the condensed consolidated balance sheets (in millions): September 30, 2020 December 31, 2019 Other current liabilities $ 2.2 $ 3.3 Other long-term liabilities 0.1 1.6 Total $ 2.3 $ 4.9

4. Intangible Assets, Goodwil_2

4. Intangible Assets, Goodwill and Other (Tables)	9 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Changes to goodwill by segment	Changes to goodwill by segment were as follows (in millions): Life Clinical Total Balances as of December 31, 2019: Goodwill $ 250.1 $ 349.2 $ 599.3 Accumulated impairment losses (41.8) (293.4) (335.2) Goodwill, net 208.3 55.8 264.1 Acquisitions (*) 29.8 — 29.8 Other adjustments (**) (2.0) — (2.0) Balances as of September 30, 2020: Goodwill 277.9 349.2 627.1 Accumulated impairment losses (41.8) (293.4) (335.2) Goodwill, net $ 236.1 $ 55.8 $ 291.9 * Acquisitions consist of $29.8 million recorded for Celsee, Inc. (see Note 2, "Acquisitions and Divestitures"). ** Goodwill decreased by $2.0 million due to the release from an escrow account setup during our acquisition of a small U.S. private company, which should have been classified as a prepaid asset in its opening balance sheet as of the March 2, 2019 acquisition date.
Schedule of identifiable purchased intangible assets with definite lives	Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions): September 30, 2020 Weighted-Average Remaining Amortization Period (years) Purchase Accumulated Net Customer relationships/lists 5.68 $ 112.8 $ (81.9) $ 30.9 Know how 5.00 192.6 (170.3) 22.3 Developed product technology 14.21 215.3 (102.2) 113.1 Licenses 7.99 65.2 (36.2) 29.0 Tradenames 7.99 6.5 (4.0) 2.5 Covenants not to compete 4.08 4.5 (1.8) 2.7 Other — 0.1 (0.1) — Total definite-lived intangible assets 597.0 (396.5) 200.5 In-process research and development 4.8 — 4.8 Total purchased intangible assets $ 601.8 $ (396.5) $ 205.3 December 31, 2019 Weighted-Average Remaining Amortization Period (years) Purchase Accumulated Net Customer relationships/lists 6.36 $ 107.2 $ (74.3) $ 32.9 Know how 5.71 188.5 (162.6) 25.9 Developed product technology 8.31 144.2 (93.9) 50.3 Licenses 8.74 76.0 (44.4) 31.6 Tradenames 8.50 6.4 (3.6) 2.8 Covenants not to compete 6.01 3.2 (1.4) 1.8 Other — 0.1 (0.1) — Total definite-lived intangible assets 525.6 (380.3) 145.3 In-process research and development 0.2 — 0.2 Total purchased intangible assets $ 525.8 $ (380.3) $ 145.5
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	Amortization expense related to purchased intangible assets is as follows (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Amortization expense $ 7.2 $ 6.0 $ 20.3 $ 17.1

6. Long-Term Debt (Tables)

6. Long-Term Debt (Tables)	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments [Table Text Block]	The principal components of long-term debt are as follows (in millions): September 30, December 31, 4.875% Senior Notes due 2020 principal amount $ 425.0 $ 425.0 Less unamortized discount and debt issuance costs (0.1) (0.6) 4.875% Senior Notes less unamortized discount and debt issuance costs 424.9 424.4 Finance leases and other debt 13.9 15.4 438.8 439.8 Less current maturities (426.6) (426.2) Long-term debt $ 12.2 $ 13.6

7. Accumulated Other Comprehe_2

7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 30, 2020
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Accumulated other comprehensive income included in our condensed consolidated balance sheets consists of the following components (in millions): Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains on available-for-sale investments Total accumulated other comprehensive income (loss) Balances as of January 1, 2020: $ (72.4) $ (22.2) $ 7.2 $ (87.4) Other comprehensive income (loss), before reclassifications 167.4 (1.3) 4.5 170.6 Amounts reclassified from Accumulated other comprehensive income — 1.8 (0.6) 1.2 Income tax effects — 0.4 (0.9) (0.5) Other comprehensive income, net of income taxes 167.4 0.9 3.0 171.3 Balances as of September 30, 2020: $ 95.0 $ (21.3) $ 10.2 $ 83.9 Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains on available-for-sale investments Total accumulated other comprehensive income (loss) Balances as of January 1, 2019: $ (35.5) $ (14.8) $ 3.3 $ (47.0) Other comprehensive (loss) income, before reclassifications (109.9) 0.1 5.1 (104.7) Amounts reclassified from Accumulated other comprehensive income — 0.6 (0.3) 0.3 Income tax effects — (0.2) (0.6) (0.8) Other comprehensive (loss) income, net of income taxes (109.9) 0.5 4.2 (105.2) Balances as of September 30, 2019: $ (145.4) $ (14.3) $ 7.5 $ (152.2)
Reclassification Out of Accumulated Other Comprehensive Income [Table Text Block]	The impact to income before taxes for amounts reclassified out of Accumulated other comprehensive income into the condensed consolidated statements of income, with presentation location, were as follows (in millions): Three Months Ended Nine Months Ended September 30, September 30, Components of Comprehensive income 2020 2019 2020 2019 Location Amortization of foreign other post-employment benefit items $ (1.1) $ (0.2) $ (1.8) $ (0.6) Other (income) expense, net Net holding gains on equity securities and available-for-sale investments $ — $ 0.2 $ 0.6 $ 0.3 Other (income) expense, net

8. Earnings Per Share (Tables)

8. Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Schedule of weighted-average common shares outstanding used to calculate basic and diluted earnings per shares and the anti-dilutive shares	The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Basic weighted average shares outstanding 29,721 29,831 29,746 29,815 Effect of potentially dilutive stock options and restricted stock awards 407 — 391 334 Diluted weighted average common shares 30,128 29,831 30,137 30,149 Anti-dilutive shares 41 95 17 56

9. Other Income and Expenses (T

9. Other Income and Expenses (Tables)	9 Months Ended
	Sep. 30, 2020
Other Income and Expenses [Abstract]
Schedule of other income (expense), net	Other (income) expense, net includes the following components (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Interest and investment income $ (1.8) $ (4.1) $ (14.6) $ (27.4) Net realized gains on investments — (0.2) (0.6) (0.2) Other-than-temporary impairment losses on investments — — 4.6 1.6 Gain on divestiture of a division — — (11.7) — Other expense (income) 0.8 (0.1) 0.8 (1.0) Other (income), net $ (1.0) $ (4.4) $ (21.5) $ (27.0)

11. Segment Information Segme_2

11. Segment Information Segment Reporting (Tables)	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Information regarding operating segments for the three months ended September 30, 2020 and 2019 is as follows (in millions): Life Clinical Other Segment net sales 2020 $ 324.0 $ 322.2 $ 1.1 2019 $ 215.7 $ 341.8 $ 3.1 Segment net profit (loss) 2020 $ 70.3 $ 38.0 $ (0.8) 2019 $ 11.6 $ 43.8 $ (0.4)	Information regarding operating segments for the nine months ended September 30, 2020 and 2019 is as follows (in millions): Life Clinical Other Segment net sales 2020 $ 803.2 $ 945.6 $ 7.0 2019 $ 643.9 $ 1,032.9 $ 10.4 Segment net profit (loss) 2020 $ 128.3 $ 100.9 $ (0.2) 2019 $ 45.9 $ 117.1 $ (1.1)
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]		The following reconciles total segment profit to consolidated income before income taxes (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Total segment profit $ 107.5 $ 55.0 $ 229.0 $ 161.9 Foreign currency exchange losses, net (0.8) (0.9) (2.5) (3.4) Net corporate operating and other expense not allocated to segments (3.6) (3.1) (10.4) (8.8) Change in fair market value of equity securities 1,580.4 (390.6) 3,591.5 1,385.0 Other income, net 1.0 4.4 21.5 27.0 Consolidated income (loss) before income taxes $ 1,684.5 $ (335.2) $ 3,829.1 $ 1,561.7

13. Restructuring Costs (Tables

13. Restructuring Costs (Tables)	9 Months Ended
	Sep. 30, 2020
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs [Table Text Block]	The following table summarizes the activity for the facility closure restructuring reserves for severance and exit costs (in millions): Balances as of December 31, 2019: $ 3.2 Cash payments (1.4) Foreign currency translation losses 0.1 Balances as of September 30, 2020: $ 1.9 The following table summarizes the activity of our European and North American reorganization restructuring reserves for severance (in millions): Life Science Clinical Diagnostics Total Balances as of December 31, 2019: $ 6.2 $ 19.1 $ 25.3 Adjustment to expense (0.6) (3.9) (4.5) Cash payments (3.8) (10.5) (14.3) Foreign currency translation losses — 0.3 0.3 Balances as of September 30, 2020: $ 1.8 $ 5.0 $ 6.8 The following table summarizes the restructuring activities related to the finance and administrative reorganization (in millions): Life Science Clinical Diagnostics Total Balances as of December 31, 2019: $ — $ — $ — Charged to expense 1.5 2.3 3.8 Adjustment to expense (0.1) (0.1) (0.2) Cash payments (0.2) (0.3) (0.5) Balances as of September 30, 2020: $ 1.2 $ 1.9 $ 3.1

14. Leases (Tables)

14. Leases (Tables)	9 Months Ended
	Sep. 30, 2020
14. Leases [Abstract]
Lease, Cost [Table Text Block]	The components of lease expense were as follows (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Operating lease cost $ 13.4 $ 14.2 $ 38.4 $ 38.7 Finance lease cost: Amortization of right-of-use assets $ 0.1 $ 0.1 $ 0.4 $ 0.5 Interest on lease liabilities 0.2 0.2 0.6 0.7 Total finance lease cost $ 0.3 $ 0.3 $ 1.0 $ 1.2 Sublease income $ 0.7 $ 0.7 $ 2.2 $ 2.2 The sublease is for a building with a term that ends in 2025, with no options to extend or renew.
Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block]	Maturities of lease liabilities were as follows (in millions): Year Ending December 31, Operating Leases Finance Leases 2020 (excluding the nine months ended September 30, 2020) $ 10.8 $ 1.2 2021 41.1 1.2 2022 33.8 1.1 2023 28.7 1.1 2024 24.8 1.1 Thereafter 111.5 13.3 Total lease payments 250.7 19.0 Less imputed interest (44.2) (7.4) Total $ 206.5 $ 11.6
Lessee Supplemental Cash Flow Information [Table Text Block]	Supplemental cash flow information related to leases was as follows (in millions): Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 10.8 $ 11.6 $ 33.0 $ 34.5 Operating cash flows from finance leases $ 0.1 $ 0.2 $ 0.4 $ 0.7 Financing cash flows from finance leases $ 0.2 $ 0.1 $ 0.6 $ 0.5 Right-of-use assets obtained in exchange for new lease obligations: Operating leases $ 0.8 $ 14.4 $ 8.4 $ 20.2 Finance leases $ 0.1 $ 0.1 $ 0.2 $ 0.1
Lessee Supplemental Balance Sheet Information [Table Text Block]	Supplemental balance sheet information related to leases was as follows (in millions): September 30, 2020 December 31, 2019 Operating Leases Operating lease right-of-use assets $ 196.7 $ 201.9 Current operating lease liabilities $ 34.4 $ 35.4 Operating lease liabilities 172.1 176.0 Total operating lease liabilities $ 206.5 $ 211.4 Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities. September 30, 2020 December 31, 2019 Finance Leases Property, plant and equipment, gross $ 11.7 $ 11.4 Less: accumulated depreciation and amortization (4.6) (4.2) Property, plant and equipment, net $ 7.1 $ 7.2 Current maturities of long-term debt and notes payable $ 0.5 $ 0.5 Long-term debt, net of current maturities 11.1 11.2 Total finance lease liabilities $ 11.6 $ 11.7 September 30, 2020 December 31, 2019 Weighted Average Remaining Lease Term Operating leases - in years 9 9 Finance leases - in years 17 18 Weighted Average Discount Rate Operating leases 4.0 % 4.2 % Finance leases 6.5 % 6.5 %

1. Basis of Presentation and _4

1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net sales	$ 647,263	$ 560,633	$ 1,755,787	$ 1,687,231
Cost of goods sold	279,952	253,607	778,120	760,674
Deferred Revenue	55,800		55,800				$ 45,800
Retained earnings	8,428,925		8,428,925				5,470,779
Accumulated other comprehensive loss	83,971		83,971				(87,348)
Total stockholders' equity	$ 8,825,145	$ 5,131,192	$ 8,825,145	$ 5,131,192	$ 7,353,402	$ 6,293,079	5,755,057	$ 5,486,810	$ 4,863,855	$ 4,020,331
Revenue Allocation Percent To Lease Elements	3.00%	3.00%	3.00%	3.00%
Additional paid-in-capital	$ 412,313		$ 412,313				410,020
Selling, general and administrative expense	198,165	$ 201,622	581,119	$ 610,460
Research and Development Expense	59,546	47,944	160,833	145,641
Interest expense	5,728	5,525	17,158	17,352
Other Nonoperating Income (Expense)	1,015	4,367	21,517	26,959
Deferred Revenue, Current	40,900		40,900				$ 33,700
Europe [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net sales	220,900	181,900	590,600	556,100
Asia Pacific [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net sales	142,000	120,700	382,300	354,300
UNITED STATES
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net sales	250,400	225,800	685,400	674,000
Americas [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net sales	$ 34,000	$ 32,200	$ 97,500	$ 102,800

1. Basis of Presentation and _5

1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Warranty accrual, beginning of period	$ 9	$ 10.1
Provision for warranty	5.4	7.3
Actual warranty costs	(6.1)	(8.4)
Warranty accrual, end of period	$ 8.3	$ 9

1. Basis of Presentation and _6

1. Basis of Presentation and Use of Estimates Capitalized Cloud Computing Arrangements (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Capitalized Cloud Computing Arrangements	$ 7	$ 3.1

1. Basis of Presentation and _7

1. Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounts Receivable, Allowance for Credit Loss	$ 19.4	$ 20.2
Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)	1.2
Allowance for Loan and Lease Losses, Write-offs	(2.1)
Accounts Receivable, Allowance for Credit Loss, Recovery	$ 0.1

2. Acquisitions (Details)

2. Acquisitions (Details) - USD ($) $ in Thousands	3 Months Ended				9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Apr. 01, 2020	Oct. 01, 2019
Business Combinations [Abstract]
Business Combination, Consideration Transferred		$ 99,300	$ 4,200
Payments to Acquire Businesses, Net of Cash Acquired			3,600
Business Combination, Contingent Consideration, Liability							$ (100)	$ (600)
Business Combination, Separately Recognized Transactions, Revenues and Gains Recognized			$ 400
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles								3,400
Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets							8,400	200
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net							300	1,400
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High							60,000
Payments to Acquire Businesses, Gross		99,200
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents							600
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities							(19,700)	$ (800)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill							79,900
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net							99,300
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets							$ 69,500
Proceeds from Divestiture of Businesses		12,200			$ 12,240	$ 0
Gain (Loss) on Disposition of Business	$ 0	11,700		$ 0	11,700	0
Business Combination, Goodwill [Abstract]
Goodwill, Acquired During Period		29,800			29,800
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization expense	7,200			$ 6,000	20,300	$ 17,100
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Liabilities
Goodwill [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Assets	400
Other Noncurrent Assets [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Assets	(300)
Other Noncurrent Liabilities [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Liabilities	300
Celsee, Inc. [Member] | Cost of Sales [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization expense	900				1,800
In Process Research and Development [Member]
Acquired Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived Intangible Assets Acquired		4,600
Developed Technology Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets Acquired		$ 70,300
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life		18 years 10 months 24 days
Customer Lists [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets Acquired		$ 3,600
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life		4 years
Customer Lists [Member] | Celsee, Inc. [Member] | Selling, General and Administrative Expenses [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization expense	200				400
Noncompete Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets Acquired		$ 1,400
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life		3 years
Noncompete Agreements [Member] | Celsee, Inc. [Member] | Selling, General and Administrative Expenses [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 100				$ 200

3. Fair Value Measurements Fair

3. Fair Value Measurements Fair Value Level Table (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2020		Sep. 30, 2020		Apr. 01, 2020	Dec. 31, 2019		Oct. 01, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized Gain on Securities		$ 1,580.3		$ 3,591.5
Debt Securities, Available-for-sale		261.3		261.3
Business Combination, Contingent Consideration, Liability						$ 0.1			$ 0.6
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value	[1]	6.6		6.6			$ 5.6
Equity Securities	[2]	8,459.3		8,459.3			4,664.4
Debt Securities, Available-for-sale	[3]	261.3		261.3			402.9
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[4]	0.6		0.6			0.9
Assets, Fair Value Disclosure		9,060		9,060			5,227.9
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[5]	1.3		1.3			1
Business Combination, Contingent Consideration, Liability	[6]	2.3		2.3			4.9
Liabilities, Fair Value Disclosure		3.6		3.6			5.9
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value	[1]	6.6		6.6			5.6
Equity Securities	[2]	8,459.3		8,459.3			4,664.4
Debt Securities, Available-for-sale	[3]	0		0			0
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[4]	0		0			0
Assets, Fair Value Disclosure		8,607.6		8,607.6			4,771.1
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[5]	0		0			0
Business Combination, Contingent Consideration, Liability	[6]	0		0			0
Liabilities, Fair Value Disclosure		0		0			0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value	[1]	0		0			0
Equity Securities	[2]	0		0			0
Debt Securities, Available-for-sale		261.3		261.3			402.9	[3]
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[4]	0.6		0.6			0.9
Assets, Fair Value Disclosure		452.4		452.4			456.8
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[5]	1.3		1.3			1
Business Combination, Contingent Consideration, Liability	[6]	0		0			0
Liabilities, Fair Value Disclosure		1.3		1.3			1
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value	[1]	0		0			0
Equity Securities	[2]	0		0			0
Debt Securities, Available-for-sale	[3]	0		0			0
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[4]	0		0			0
Assets, Fair Value Disclosure		0		0			0
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[5]	0		0			0
Business Combination, Contingent Consideration, Liability	[6]	2.3		2.3			4.9
Liabilities, Fair Value Disclosure		2.3		2.3			4.9
US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure		0		0
Asset-backed Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	0.1		0.1			0.1
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	0		0			0
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	0.1		0.1			0.1
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	0		0			0
Commercial Paper [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	108.8		108.8			42.9
Commercial Paper [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	0		0			0
Commercial Paper [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	108.8		108.8			42.9
Commercial Paper [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	0		0			0
Time Deposits [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	24.6		24.6			41.2
Time Deposits [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	14.6		14.6			31.2
Time Deposits [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	10		10			10
Time Deposits [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	0		0			0
Money Market Funds [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	127.1		127.1			69.9
Money Market Funds [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	127.1		127.1			69.9
Money Market Funds [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	0		0			0
Money Market Funds [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	0		0			0
Cash Equivalents [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	332.2		332.2			154.1
Cash Equivalents [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	141.7		141.7			101.1
Cash Equivalents [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	190.5		190.5			53
Cash Equivalents [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	0		0			0
US Treasury Securities | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure		71.6		71.6
US Treasury Securities | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure		71.6		71.6
US Treasury Securities | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure		0		0
Foreign Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		2.1	[3]	2.1	[3]		3.1
Foreign Government Debt [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0	[3]	0	[3]		0
Foreign Government Debt [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		2.1	[3]	2.1	[3]		3.1
Foreign Government Debt [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0	[3]	0	[3]		0
Municipal Obligations (Member) | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	13.4		13.4			11.6
Municipal Obligations (Member) | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	0		0			0
Municipal Obligations (Member) | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	13.4		13.4			11.6
Municipal Obligations (Member) | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	0		0			0
Foreign Government Obligations [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	5		5			4.7
Foreign Government Obligations [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	0		0			0
Foreign Government Obligations [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	5		5			4.7
Foreign Government Obligations [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	0		0			0
Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	114.4		114.4			204.5
Corporate Debt Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	0		0			0
Corporate Debt Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	114.4		114.4			204.5
Corporate Debt Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	0		0			0
US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	78.2		78.2			106.1
US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	0		0			0
US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	78.2		78.2			106.1
US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	0		0			0
Asset-backed Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	48.2		48.2			72.9
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	0		0			0
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	48.2		48.2			72.9
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	0		0			0
Other Current Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	[6]	2.2		2.2			3.3
Other Noncurrent Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	[6]	0.1		0.1			1.6
Short-term Investments [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	[2]	53		53			51
Debt Securities, Available-for-sale	[3]	261.2		261.2			402.8
Short-term Investments [Member] | Foreign Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		2.1		2.1			3.1
Short-term Investments [Member] | Municipal Obligations (Member) | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		13.4		13.4			11.6
Short-term Investments [Member] | Foreign Government Obligations [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		5		5			4.7
Short-term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		114.4		114.4			204.5
Short-term Investments [Member] | US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		78.2		78.2			106.1
Short-term Investments [Member] | Asset-backed Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		48.1		48.1			72.8
Other Investments [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		1		1			0
Equity Securities	[2]	8,406.3		8,406.3			4,613.4
Debt Securities, Available-for-sale	[3]	0.1		0.1			0.1
Restricted investment [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		5.6		5.6			$ 5.6
Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		1.6		1.6
Sales milestone minimum amount [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low		$ 0		$ 0
[1]	Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions): September 30, 2020 December 31, 2019 Restricted investments $ 5.6 $ 5.6 Other investments 1.0 — Total $ 6.6 $ 5.6
[2]	Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions): September 30, 2020 December 31, 2019 Short-term investments $ 53.0 $ 51.0 Other investments 8,406.3 4,613.4 Total $ 8,459.3 $ 4,664.4
[3]	Available-for-sale investments are included in the following accounts in the condensed consolidated balance sheets (in millions): September 30, 2020 December 31, 2019 Short-term investments $ 261.2 $ 402.8 Other investments 0.1 0.1 Total $ 261.3 $ 402.9
[4]	Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets.
[5]	Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets.
[6]	Contingent consideration liability is included in the following accounts in the condensed consolidated balance sheets (in millions): September 30, 2020 December 31, 2019 Other current liabilities $ 2.2 $ 3.3 Other long-term liabilities 0.1 1.6 Total $ 2.3 $ 4.9
[7]	Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.

3. Fair Value Measurements 3. C

3. Fair Value Measurements 3. Contingent Consideration (Details) - USD ($) $ in Millions		3 Months Ended			9 Months Ended
		Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2020	Apr. 01, 2020	Dec. 31, 2019	Oct. 01, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value		$ 2.3			$ 2.3		$ 4.9
Business Combination, Contingent Consideration, Liability						$ 0.1		$ 0.6
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High						60
Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration milestone payments		(0.4)		$ (1.3)	(1.7)
Business Combination, Contingent Consideration, Liability		1.6			1.6
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances					(1)
Distributor [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration milestone payments		(1.4)	$ (0.7)
Business Combination, Contingent Consideration, Liability		0.6			0.6
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances		0
Celsee
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		0.1			0.1	0.1
Business Combination, Contingent Consideration, Liability, Noncurrent						$ 0.1
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		$ 60			$ 60
Sales milestone percentage of annual invoices [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Contingent Consideration, Potential Percentage Payout		39.00%			39.00%
Sales milestone percentage of annual invoices low [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Contingent Consideration, Potential Percentage Payout		20.00%			20.00%
Sales milestone minimum amount [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low		$ 0			$ 0
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	[1]	2.3			2.3		4.9
Other Noncurrent Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	[1]	0.1			0.1		1.6
Other Current Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	[1]	$ 2.2			$ 2.2		$ 3.3
[1]	Contingent consideration liability is included in the following accounts in the condensed consolidated balance sheets (in millions): September 30, 2020 December 31, 2019 Other current liabilities $ 2.2 $ 3.3 Other long-term liabilities 0.1 1.6 Total $ 2.3 $ 4.9

3. Foreign Exchange Forward Con

3. Foreign Exchange Forward Contracts (Details) $ in Millions	9 Months Ended
	Sep. 30, 2020USD ($)
Forward foreign exchange contract to sell foreign currency [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	$ 75.6
Gain (Loss) on Foreign Currency Derivative Instruments not Designated as Hedging Instruments	0.1
Forward foreign exchange contract to purchase foreign currency [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	272.4
Gain (Loss) on Foreign Currency Derivative Instruments not Designated as Hedging Instruments	$ (0.9)

3. Available-for-Sale Investmen

3. Available-for-Sale Investments (Details) - USD ($) $ in Millions		Sep. 30, 2020		Dec. 31, 2019
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		$ 255.2
Debt Securities, Available-for-sale		261.3
Fair Value, Recurring [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		255.2		$ 400.9
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		6.2		2.4
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(0.1)		(0.4)
Debt Securities, Available-for-sale, Allowance for Credit Loss		0
Debt Securities, Available-for-sale	[1]	261.3		402.9
Fair Value, Recurring [Member] | Corporate Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	114.4		204.5
Fair Value, Recurring [Member] | Municipal obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	13.4		11.6
Fair Value, Recurring [Member] | US Government Sponsored Agencies [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	78.2		106.1
Fair Value, Recurring [Member] | Foreign Government Obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	5		4.7
Fair Value, Recurring [Member] | Foreign Government Debt [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale		2.1	[1]	3.1
Fair Value, Recurring [Member] | Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	48.2		72.9
Fair Value, Recurring [Member] | Other Long-term Investments [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		0.1		0.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0		0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0		0
Debt Securities, Available-for-sale, Allowance for Credit Loss		0
Debt Securities, Available-for-sale		0.1		0.1
Fair Value, Recurring [Member] | Other Long-term Investments [Member] | Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		0.1		0.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0		0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0		0
Debt Securities, Available-for-sale, Allowance for Credit Loss		0
Debt Securities, Available-for-sale		0.1		0.1
Fair Value, Recurring [Member] | Short-term Investments [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		255.1		400.8
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		6.2		2.4
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(0.1)		(0.4)
Debt Securities, Available-for-sale, Allowance for Credit Loss		0
Debt Securities, Available-for-sale	[1]	261.2		402.8
Fair Value, Recurring [Member] | Short-term Investments [Member] | Corporate Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		111.5		203.2
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		2.9		1.4
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0		(0.1)
Debt Securities, Available-for-sale, Allowance for Credit Loss		0
Debt Securities, Available-for-sale		114.4		204.5
Fair Value, Recurring [Member] | Short-term Investments [Member] | Municipal obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		13.2		11.5
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0.2		0.1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0		0
Debt Securities, Available-for-sale, Allowance for Credit Loss		0
Debt Securities, Available-for-sale		13.4		11.6
Fair Value, Recurring [Member] | Short-term Investments [Member] | US Government Sponsored Agencies [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		75.6		105.6
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		2.6		0.7
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0		(0.2)
Debt Securities, Available-for-sale, Allowance for Credit Loss		0
Debt Securities, Available-for-sale		78.2		106.1
Fair Value, Recurring [Member] | Short-term Investments [Member] | Foreign Government Obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		4.9		4.7
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0.1		0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0		0
Debt Securities, Available-for-sale, Allowance for Credit Loss		0
Debt Securities, Available-for-sale		5		4.7
Fair Value, Recurring [Member] | Short-term Investments [Member] | Foreign Government Debt [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		2.1		3.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0		0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0		0
Debt Securities, Available-for-sale, Allowance for Credit Loss		0
Debt Securities, Available-for-sale		2.1		3.1
Fair Value, Recurring [Member] | Short-term Investments [Member] | Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		47.8		72.7
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0.4		0.2
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(0.1)		(0.1)
Debt Securities, Available-for-sale, Allowance for Credit Loss		0
Debt Securities, Available-for-sale		48.1		72.8
Fair Value, Recurring [Member] | Other Investments [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	$ 0.1		$ 0.1
[1]	Available-for-sale investments are included in the following accounts in the condensed consolidated balance sheets (in millions): September 30, 2020 December 31, 2019 Short-term investments $ 261.2 $ 402.8 Other investments 0.1 0.1 Total $ 261.3 $ 402.9

3. Amortized Cost and Fair Valu

3. Amortized Cost and Fair Value of Debt Securities (Details) $ in Millions	Sep. 30, 2020USD ($)
Fair Value Disclosures [Abstract]
Mature in less than one year	$ 95
Mature in one to five years	113.5
Mature in more than five years	46.7
Total Amortized Cost	255.2
Mature in less than one year	95.7
Mature in one to five years	116.4
Mature in more than five years	49.2
Estimated Fair Value	$ 261.3

3. Fair Value and Gross Unreali

3. Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	$ 0.1	$ 0.4
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	0	0.1
Debt Securities, Available-for-sale, Unrealized Loss Position	6.9	111.8
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months	6.9	91.9
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer	0	19.9
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	0.1	0.3
Corporate Debt Securities [Member]
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax		0.1
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss		0
Debt Securities, Available-for-sale, Unrealized Loss Position		48.6
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months		46.5
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer		2.1
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss		0.1
US Government Sponsored Agencies [Member]
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax		0.2
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss		0
Debt Securities, Available-for-sale, Unrealized Loss Position		38.3
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months		27.5
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer		10.8
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss		0.2
Asset-backed Securities [Member]
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	0.1	0.1
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	0	0.1
Debt Securities, Available-for-sale, Unrealized Loss Position	6.9	24.9
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months	6.9	17.9
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer	0	7
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	0.1	$ 0
Fair Value, Recurring [Member] | Debt Securities [Member]
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	$ 0.1

3. Fair Value Financial Instrum

3. Fair Value Financial Instruments (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest Receivable, Current	$ 1.5	$ 2
Equity Securities without Readily Determinable Fair Value, Amount	$ 0.5	0.3
Ordinary voting shares [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investment ownership percentage	37.00%
Investment Owned, Balance, Shares	12,987,900
Preference shares [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investment ownership percentage	28.00%
Investment Owned, Balance, Shares	9,588,908
Carrying (Reported) Amount, Fair Value Disclosure [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total long-term debt, excluding capital leases and current maturities	$ 424.9	424.4
Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total long-term debt, excluding capital leases and current maturities	$ 429	$ 435.5

4. Intangible Assets, Goodwil_3

4. Intangible Assets, Goodwill and Other (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2019
Goodwill [Line Items]
Goodwill		$ 627,100	$ 599,300
Accumulated impairment loss		(335,200)	(335,200)
Goodwill, net		291,916	264,131
Goodwill, Acquired During Period	$ 29,800	29,800
Goodwill, Other Increase (Decrease)		2,000
Life Science [Member]
Goodwill [Line Items]
Goodwill		277,900	250,100
Accumulated impairment loss		(41,800)	(41,800)
Goodwill, net		236,100	208,300
Goodwill, Acquired During Period	29,800	29,800
Goodwill, Other Increase (Decrease)	$ 2,000	2,000
Clinical Diagnostics [Member]
Goodwill [Line Items]
Goodwill		349,200	349,200
Accumulated impairment loss		(293,400)	(293,400)
Goodwill, net		55,800	$ 55,800
Goodwill, Acquired During Period		0
Goodwill, Other Increase (Decrease)		$ 0

4. Intangible Assets, Goodwil_4

4. Intangible Assets, Goodwill and Other Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Oct. 01, 2019
Acquired Finite-Lived Intangible Assets [Line Items]
Goodwill, Acquired During Period		$ 29.8		$ 29.8
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 597			597		$ 525.6
Accumulated Amortization	(396.5)			(396.5)		(380.3)
Net Carrying Amount	200.5			200.5		145.3
Amortization [Abstract]
Amortization expense	7.2		$ 6	20.3	$ 17.1
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles							$ 3.4
Intangible Assets, Gross (Excluding Goodwill)	601.8			$ 601.8		$ 525.8
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period				5 years 8 months 4 days		6 years 4 months 9 days
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	112.8			$ 112.8		$ 107.2
Accumulated Amortization	(81.9)			(81.9)		(74.3)
Net Carrying Amount	30.9			$ 30.9		$ 32.9
Know How [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period				5 years		5 years 8 months 15 days
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	192.6			$ 192.6		$ 188.5
Accumulated Amortization	(170.3)			(170.3)		(162.6)
Net Carrying Amount	22.3			$ 22.3		$ 25.9
Developed Technology Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period				14 years 2 months 15 days		8 years 3 months 21 days
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	215.3			$ 215.3		$ 144.2
Accumulated Amortization	(102.2)			(102.2)		(93.9)
Net Carrying Amount	113.1			$ 113.1		$ 50.3
Licensing Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period				7 years 11 months 26 days		8 years 8 months 26 days
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	65.2			$ 65.2		$ 76
Accumulated Amortization	(36.2)			(36.2)		(44.4)
Net Carrying Amount	29			$ 29		$ 31.6
Trade Names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period				7 years 11 months 26 days		8 years 6 months
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	6.5			$ 6.5		$ 6.4
Accumulated Amortization	(4)			(4)		(3.6)
Net Carrying Amount	2.5			$ 2.5		$ 2.8
Noncompete Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period				4 years 29 days		6 years 3 days
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	4.5			$ 4.5		$ 3.2
Accumulated Amortization	(1.8)			(1.8)		(1.4)
Net Carrying Amount	2.7			$ 2.7		$ 1.8
Other Intangible Assets [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	0.1			$ 0.1		$ 0.1
Accumulated Amortization	(0.1)			(0.1)		(0.1)
Net Carrying Amount	0			0		0
In Process Research and Development [Member]
Amortization [Abstract]
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 4.8			$ 4.8		$ 0.2

6. Long-Term Debt (Details)

6. Long-Term Debt (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2020	Dec. 31, 2019	Dec. 31, 2010
Debt Instrument [Line Items]
Debt and Lease Obligation	$ 438,800	$ 439,800
Other Long-term Debt, Current	426,600	426,200
Long-term debt, net of current maturities	12,241	13,579
Unsecured Debt [Member] | Senior Notes 4.875% due 2020 [Member]
Debt Instrument [Line Items]
Unsecured Debt	425,000	425,000
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$ 100	600
Debt Instrument, Interest Rate, Stated Percentage			4.875%
Debt Instrument, Redemption Price, Percentage	100.00%
Long-term debt	$ 424,900	424,400	$ 422,600
Debt Instrument, Interest Rate, Effective Percentage			4.946%
Face amount of debt sold			$ 425,000
Finance Lease Obligations [Member] | Finance Leases and Other Debt [Member]
Debt Instrument [Line Items]
Other Long-term Debt	13,900	$ 15,400
Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit maximum borrowing capacity	200,000
Outstanding borrowings	$ 0
Line of Credit Facility, Interest Rate at Period End	1.355%
Standby Letters of Credit [Member]
Debt Instrument [Line Items]
Line of credit maximum borrowing capacity	$ 200

7. Accumulated Other Comprehe_3

7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income			$ (87,348)
Total other comprehensive income (loss) net of tax	$ 145,113	$ (102,540)	171,319	$ (105,155)
Ending balance, Accumulated other comprehensive income	83,971		83,971
Other (income) expense, net	(1,015)	(4,367)	(21,517)	(26,959)
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income			(72,400)	(35,500)
Other Comprehensive Income (Loss), before Reclassifications, before Tax			167,400	(109,900)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax			0	0
Other Comprehensive Income (Loss), Tax			0	0
Total other comprehensive income (loss) net of tax			167,400	(109,900)
Ending balance, Accumulated other comprehensive income	95,000	(145,400)	95,000	(145,400)
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income			(22,200)	(14,800)
Other Comprehensive Income (Loss), before Reclassifications, before Tax			(1,300)	100
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax			1,800	600
Other Comprehensive Income (Loss), Tax			400	(200)
Total other comprehensive income (loss) net of tax			900	500
Ending balance, Accumulated other comprehensive income	(21,300)	(14,300)	(21,300)	(14,300)
Accumulated Defined Benefit Plans Adjustment [Member] | Reclassification Out Of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other (income) expense, net	(1,100)	(200)	(1,800)	(600)
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income			7,200	3,300
Other Comprehensive Income (Loss), before Reclassifications, before Tax			4,500	5,100
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax			(600)	(300)
Other Comprehensive Income (Loss), Tax			(900)	(600)
Total other comprehensive income (loss) net of tax			3,000	4,200
Ending balance, Accumulated other comprehensive income	10,200	7,500	10,200	7,500
Accumulated Net Unrealized Investment Gain (Loss) [Member] | Reclassification Out Of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other (income) expense, net	0	(200)	(600)	(300)
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income			(87,400)	(47,000)
Other Comprehensive Income (Loss), before Reclassifications, before Tax			170,600	(104,700)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax			1,200	300
Other Comprehensive Income (Loss), Tax			(500)	(800)
Total other comprehensive income (loss) net of tax			171,300	(105,200)
Ending balance, Accumulated other comprehensive income	$ 83,900	$ (152,200)	$ 83,900	$ (152,200)

8. Earnings Per Share (Details)

8. Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Basic weighted average shares outstanding	29,721	29,831	29,746	29,815
Effect of potentially dilutive stock options and restricted stock awards	407	0	391	334
Diluted weighted average common shares	30,128	29,831	30,137	30,149
Anti-dilutive shares	41	95	17	56

9. Other Income and Expenses (D

9. Other Income and Expenses (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Interest and investment income	$ (1,800)		$ (4,100)	$ (14,600)	$ (27,400)
Net realized (gain) loss on investments	0		(200)	(600)	(200)
Other Nonoperating (Income)			(100)		(1,000)
Other Nonoperating Expense	800			800
Equity Method Investment, Other than Temporary Impairment	0		0	4,600	1,600
Gain on Disposition of a division	0	$ (11,700)	0	(11,700)	0
Other Nonoperating Income (Expense)	$ 1,015		$ 4,367	$ 21,517	$ 26,959

10. Income Taxes (Details)

10. Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Effective tax rate	21.90%	22.80%	22.50%	22.80%
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit	$ 4.7		$ 4.7
Unrecognized Tax Benefits	$ 54.4		54.4		$ 39.2
Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions			$ 13.3

Segment Reporting (Details)

Segment Reporting (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Segment Reporting Information [Line Items]
Net sales	$ 647,263	$ 560,633	$ 1,755,787	$ 1,687,231
Income before income taxes	1,684,461	(335,216)	3,829,105	1,561,651
Life Science [Member]
Segment Reporting Information [Line Items]
Net sales	324,000	215,700	803,200	643,900
Income before income taxes	70,300	11,600	128,300	45,900
Clinical Diagnostics [Member]
Segment Reporting Information [Line Items]
Net sales	322,200	341,800	945,600	1,032,900
Income before income taxes	38,000	43,800	100,900	117,100
Other Segments [Member]
Segment Reporting Information [Line Items]
Net sales	1,100	3,100	7,000	10,400
Income before income taxes	$ (800)	$ (400)	$ (200)	$ (1,100)

11. Segment Information Segme_3

11. Segment Information Segment Profit Reconciliations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	$ 1,684,461	$ (335,216)	$ 3,829,105	$ 1,561,651
Marketable Securities, Unrealized Gain (Loss)	1,580,350	(390,620)	3,591,509	1,384,999
Operating Segments [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	107,500	55,000	229,000	161,900
Corporate, Non-Segment [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	(3,600)	(3,100)	(10,400)	(8,800)
Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Marketable Securities, Unrealized Gain (Loss)	1,580,400	(390,600)	3,591,500	1,385,000
Foreign Currency Gain (Loss) [Member] | Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	(800)	(900)	(2,500)	(3,400)
Other Nonoperating Income (Expense) [Member] | Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	$ 1,000	$ 4,400	$ 21,500	$ 27,000

11. Segment Information Segme_4

11. Segment Information Segment Asset Reconciliation (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	$ 12,020,931	$ 8,008,859

13. Restructuring Costs (Detail

13. Restructuring Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		11 Months Ended	22 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Cost of goods sold	$ 279,952	$ 253,607	$ 778,120	$ 760,674
Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	1,900		1,900		$ 1,900	$ 1,900	$ 3,200
Restructuring Charges						4,000
Restructuring Reserve, Accrual Adjustment	0		0
Payments for Restructuring			(1,400)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss			100
European and North American Reorganization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	6,800		6,800		6,800	6,800	25,300
Restructuring Charges					20,800
Restructuring Reserve, Accrual Adjustment	(1,000)		(4,500)
Payments for Restructuring			(14,300)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss			300
European and North American Reorganization [Member] | Life Science [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	1,800		1,800		1,800	1,800	6,200
Restructuring Reserve, Accrual Adjustment			(600)
Payments for Restructuring			(3,800)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss			0
European and North American Reorganization [Member] | Clinical Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	5,000		5,000		5,000	5,000	19,100
Restructuring Reserve, Accrual Adjustment			(3,900)
Payments for Restructuring			(10,500)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss			300
Finance and Administrative Reorganization
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	3,100		3,100		3,100	3,100	0
Restructuring Charges			3,800
Restructuring Reserve, Accrual Adjustment			(200)
Payments for Restructuring			(500)
Finance and Administrative Reorganization | Selling, General and Administrative Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges			3,600
Restructuring Reserve, Accrual Adjustment	(200)
Finance and Administrative Reorganization | Life Science [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	1,200		1,200		1,200	1,200	0
Restructuring Charges			1,500
Restructuring Reserve, Accrual Adjustment			(100)
Payments for Restructuring			(200)
Finance and Administrative Reorganization | Clinical Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$ 1,900		1,900		$ 1,900	$ 1,900	$ 0
Restructuring Charges			2,300
Restructuring Reserve, Accrual Adjustment			(100)
Payments for Restructuring			$ (300)

14. Leases (Details)

14. Leases (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Lessee, Lease, Description [Line Items]
Operating Lease, Cost	$ 13,400	$ 14,200	$ 38,400	$ 38,700
Finance Lease, Right-of-Use Asset, Amortization	100	100	400	500
Finance Lease, Interest Expense	200	200	600	700
Finance Lease Cost	300	300	1,000	1,200
Sublease Income	700	700	2,200	2,200
Operating Lease, Payments	10,800	11,600	33,000	34,500
Finance Lease, Interest Payment on Liability	100	200	400	700
Finance Lease, Principal Payments	200	100	600	500
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	800	14,400	8,400	20,200
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability	100	$ 100	200	$ 100
Operating lease right-of-use assets	196,652		196,652		$ 201,868
Current operating lease liabilities	34,387		34,387		35,365
Operating lease liabilities	172,144		172,144		176,018
Operating Lease, Liability	206,500		206,500		211,400
Finance Lease, Right-Of-Use Asset, before Accumulated Amortization	11,700		11,700		11,400
Finance Lease, Right-Of-Use Asset, Accumulated Amortization	4,600		4,600		4,200
Finance Lease, Right-Of-Use Asset, after Accumulated Amortization	7,100		7,100		7,200
Finance Lease, Liability, Current	500		500		500
Finance Lease, Liability, Noncurrent	11,100		11,100		11,200
Finance Lease, Liability	$ 11,600		$ 11,600		$ 11,700
Operating Lease, Weighted Average Remaining Lease Term	9 years		9 years		9 years
Finance Lease, Weighted Average Remaining Lease Term	17 years		17 years		18 years
Operating Lease, Weighted Average Discount Rate, Percent	4.00%		4.00%		4.20%
Finance Lease, Weighted Average Discount Rate, Percent	6.50%		6.50%		6.50%
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year	$ 10,800		$ 10,800
Finance Lease, Liability, Payments, Remainder of Fiscal Year	1,200		1,200
Lessee, Operating Lease, Liability, to be Paid, Year One	41,100		41,100
Finance Lease, Liability, to be Paid, Year One	1,200		1,200
Lessee, Operating Lease, Liability, Payments, Due Year Two	33,800		33,800
Finance Lease, Liability, Payments, Due Year Two	1,100		1,100
Lessee, Operating Lease, Liability, Payments, Due Year Three	28,700		28,700
Finance Lease, Liability, Payments, Due Year Three	1,100		1,100
Lessee, Operating Lease, Liability, Payments, Due Year Four	24,800		24,800
Finance Lease, Liability, Payments, Due Year Four	1,100		1,100
Lessee, Operating Lease, Liability, Payments, Due after Year Five	111,500		111,500
Finance Lease, Liability, Payments, Due after Year Five	13,300		13,300
Lessee, Operating Lease, Liability, Payments, Due	250,700		250,700
Finance Lease, Liability, Payment, Due	19,000		19,000
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	(44,200)		(44,200)
Finance Lease, Liability, Undiscounted Excess Amount	$ (7,400)		$ (7,400)
Minimum [Member]
Lessee, Lease, Description [Line Items]
Lessee Operating And Finance Leases Remaining Lease Term			1 year
Maximum [Member]
Lessee, Lease, Description [Line Items]
Lessee Operating And Finance Leases Remaining Lease Term			19 years